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Chapter I 
INTRODUCTION AND PROBLEM STATEMENT 
Organ transplantation as a method to replace an irreversibly 
lost organ function is a relatively new development in medicine. 
Although especially by kidney transplantation it has been possible 
to save the lives and restore the health of thousands of patients, 
rejection of the grafted organ as well as the side-effects of 
drugs given to prevent rejection, remain the main obstacle in 
clinical transplantation. 
Since the work of Medawar it has been known that rejection 
as a process of graft destruction is brought about by a complexi-
ty of immune processes of cellular and humoral nature (Russell and 
Winn, 1970) . The greater part of our present knowledge about these 
immune reactions is based on research in experimental animals. It 
has become firmly established that graft survival can be improved 
by decreasing the immune capacity of the recipient. This principle 
has been successfully applied in clinical practice, and it is now 
clear that immunosuppression of the recipient can lead to a long 
lasting graft acceptance in a considerable part of transplanted 
patients. 
In spite of these results, the currently used immunosuppres-
sive regimes are far from specific. They do not only suppress the 
immune response of the host to the foreign graft but, by impairing 
the immune capacity as a whole, they also undermine the resistance 
to all foreign invaders of bacterial, viral or mycotic nature. 
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Furthermore, the doses of immunosuppressive drugs often have to 
be so high that the recipient is exposed to their many adverse 
side-effects. For these reasons an effective prevention or treat-
ment of rejection reactions may, in fact, endanger the life of the 
recipient of a grafted organ. 
In this position it would be a big step forward to have at 
one's disposal a therapy which would only block immune reactivity 
to the graft, while leaving the immune potential of the host as 
such unimpaired. Such a phenomenon of specific immune suppression 
has been known for years in experimental models. In many species 
it is possible to prolong graft survival by administering anti-
bodies directed specifically against the graft antigens. This 
method is called enhancement (Feldman, 1972) . However, the clini-
cal use of enhancing antibodies is impeded by the well-known fact 
that circulating antibodies may also lead to hyperacute rejection 
or to shortening of graft survival in experimental and in clinical 
transplantation. 
In our laboratory we were able to develop an experimental 
model in which both immunological phenomena, enhancement as well 
as hyperacute graft destruction, could be induced with the same 
alloantiserum (Koene et al., 1973; Gerlag, 1975). Our results 
raised the question whether different antibodies present in the 
same alloantiserum might be responsible for its apparently oppo-
si'te biological actions on grafts. 
We, therefore, decided to undertake the experiments to be 
reported here. What we wanted to study was the possibility of 
separating the two biological activities of our alloantisera by 
isolation of the different antibody populations assumed. Such a 
separation could be obtained in two ways. A first approach would 
be fractionation of alloantisera in classes and subclasses of 
immunoglobulins. Separation of antibodies with a distinct immuno-
logical specificity would be a second means of isolation. Enhance-
ment and acute destruction of grafts can be most easily elicited 
by the administration of hyperimmune sera. These sera contain 
predominantly IgG immunoglobulins and most reports in the litera-
ture suggest that this IgG antibody fraction is active in both 
phenomena. Therefore in the experiments reported here we have con-
io 
fined ourselves to the study of IgG and its subclasses. 
It should be borne in mind that our approach starts from the 
presumption of two separable fractions, whereas it might be pos-
sible, theoretically, that either effect is exerted by one single 
antibody population and depends on the circumstances under which 
these antibodies interact with the graft antigens. From this point 
of view, a failure to effect the desired separation would strong-
ly favour the latter alternative hypothesis. 
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Chapter II 
STRUCTURE AND SEPARATION OF IMMUNOGLOBULINS 
INTRODUCTION 
The exposure of vertebrates to foreign antigenic substances 
usually results in the elaboration of antibodies specifically 
directed against these antigens. These humoral antibodies are 
produced by В lymphocytes and they are called immunoglobulins 
(Heremans, 1959). Porter (1962) demonstrated that in the rabbit 
the immunoglobulins were composed of pairs of polypeptide chains, 
H (heavy)-chains and L (light)-chains. These chains are linked to 
each other by disulfide bridges (figure 1). Later on, this same 
concept was also accepted for the other vertebrates. 
By reduction (Fleischman et al, 1962) and enzymatic proteo­
lysis (Porter, 1959; Nisonoff et al., I960) the immunoglobulin 
molecule can be divided into several fragments. Splitting of the 
disulfide bridges by reduction with excess of a sulphydryl reagent, 
and breaking of the non-covalent forces which hold together the 
reduced molecules, by lowering the pH, reveals the distinct pep­
tide chains (H and L chains). These chains can be separated by 
molecular sieving. Proteolytic digestion with enzymes like papaine 
en pepsine splits the IgG molecule, approximately in the middle 
of the H chain. Papaine digestion results in the formation of two 
identical antigen binding fragments, called Fab fragments and one 
crystallisable fragment, called Fc fragment. The Fab fragment com­
prises the L chain and the aminoterminal part of the H chain, the 
so called Fd fragment. Pepsine splits the IgG molecule at the 
carboxy terminal site of the disulfide bridges, linking the H chains. 
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Figure 1. Outl ine of the s t r u c t u r e of the IgG molecule. Cleavage po in t s of 
enzymatic d iges t ion are ind ica ted by arrows. 
As a r e s u l t of pepsine d iges t ion , a fragment i s formed which con-
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t a in s both antigen binding regions , t h i s i s ca l led F(ab') . The 
res idua l pa r t of the immunoglobulin molecule i s completely frag-
mentated. 
Besides the inter-chain disulfjde bridges, which connect H 
chain and L chain, there are also intra-chain disulfide bridges 
in the complete immunoglobulin molecule. By these intra-chain 
disulfide bonds, the immunoglobulin molecule is divided into homo-
logous regions which are identical in size, these are called 
domains (Edelman et al., 1969). It is accepted that particular 
biological activities of the immunoglobulins are mediated by 
structures of particular domains. 
Amino acid analysis and sequence studies of the immunoglobulin 
14 
molecule have revealed that the amino terminal ends of the H chain 
and of the L chain constitute regions of higher variability in 
amino acid composition. This part of the antibody molecule is 
therefore called the variable (V) region, whereas the remaining 
parts of the polypeptide chains are indicated by the term С (con­
stant) region (figure 1). The variability in the V region deter­
mines the specificity and the affinity of the antibody molecule. 
On the basis of differences in the constant parts of the 
H chains, the immunoglobulins can be divided into classes and sub­
classes. The constant part has a specific amino acid sequence 
which is typical for every class or subclass. The different amino 
acid sequences are responsible for the antigenic structures which 
can be identified by antisera specifically directed against these 
antigens. Similar structural and antigenic differences are also 
present in the constant part of the L chains. These differences 
enable us to make a further distinction in so-called L chain 
types (< and λ). 
BIOLOGICAL ACTIVITY OF THE IMMUNOGLOBULINS 
The biological activity of the immunoglobulins can be dis­
tinguished in a primary function and a secondary function. The 
primary function comprises the specific recognition and binding 
of antigen mediated by the variable part of the immunoglobulin 
molecule. A number of biological events follow the initial binding 
of antigen to antibody and these are called the secondary functions. 
As mentioned before, these separate activities such as,complement 
activation, binding with macrophages etc. are mediated by struc­
tures of particular domains of the imraUnoglobulin molecule. Not 
all the different biologic activities of the immunoglobulins will 
be reviewed in this chapter. For this we refer to Spiegelberg 
(1974). We would rather focus attention on those activities that 
are of importance in the transplantation reactions in the mouse. 
IMMUNOGLOBULIN CLASSES AND SUBCLASSES 
Analysis of the antigenic properties of the immunoglobulins 
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reveals much of what is our present day knowledge of this group 
of proteins. Isotypic variations in the heavy chains allow classi­
fication of the immunoglobulins in classes and subclasses. Al­
though the differentiation into classes and subclasses may be 
somewhat arbitrary, classes are defined as groups of immunoglobu­
lins with distinct antigenic properties reflecting major struc­
tural differences in the carboxy terminal part of the heavy chains, 
associated with distinct biological properties (Cohen and Milstein, 
1967) . Additional minor antigenic differences enable us to make 
a further distinction in subclasses. 
Some classes of immunoglobulins differ also in their physico-
chemical properties. IgM for example has a molecular weight 
approximately six times that of IgG. Differences in electrophore-
tic mobility may serve too, as a means to identify classes and 
subclasses. In the mouse, for example, it is possible to differ­
entiate the fast anodal IgGl and the slow cathodal IgG2, by immuno-
electrophoresis. However, it has to be stressed that especially 
with regard to IgG, a complete isolation of the subclasses on the 
basis of physicochemical differences is not feasible. 
PHYSICOCHEMICAL HETEROGENEITY OF THE IMMUNOGLOBULINS 
One of the most striking features of the immunoglobulins is 
their heterogeneity in physicochemical behaviour (Fahey, 1962). 
This heterogeneity is primarily caused by variations in amino 
acid composition and amino acid sequence and by differences in the 
number of carbohydrate residues present in the immunoglobulin 
molecules. Variation of these structures results in differences 
of shape, density and electric charge of the molecules. These * 
variations can also be found in immunoglobulin molecules of a 
single (sub)class. 
It may be important to discuss this point, because many in­
vestigators have tried to isolate classes and subclasses by mean 
of techniques based on differences in shape, charge and mobilit· 
of the molecules to be separated. Although remarkable differenc 
in molecular weight between IgM and IgG allow a purification о 
the basis of their size, a further isolation of the subclasses 
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based on differences in physicochemical properties is almost im­
possible. The electrophoretic heterogeneity of antibodies was 
already demonstrated in 1960 by Askonas et al. (1960). They showed 
that electrophoresis of antibodies with the same specificity re­
sulted in multiple peaks in the whole γ-globulin region. This 
heterogeneity in electrochemical behaviour was also reflected by 
the results of ion exchange chromatography. That these differences 
are not only caused by different class and subclass determining 
structures on the constant parts of the H chains was demonstrated 
by Reisfeld and Small (1966). They found that not only the iso­
lated H chains but also the L chains of antibody molecules with 
the same specificity had a heterogeneity in their electrophoretic 
patterns similar to that of the intact immunoglobulin molecule. 
It is, therefore, assumed that the variations, occurring in the 
variable parts of heavy and light chains, independent of (sub)-
class, may sometimes have much greater influence on the physico-
chemical properties than the structures determining the (sub)class. 
Using affinity labelling, Doolittle and Singer (1965) demonstrated 
that the amino acid composition at the antigen binding sites of 
both chains of immunoglobulin molecules having the same specifi­
city may vary from molecule to molecule. The number of differing 
antibody molecules sharing the same anti-hapten specificity pro­
duced by inbred mouse strains, was calculated by Kreth and 
Williamson (1973) to be some thousands. 
Extensive chemical analysis using fingerprint techniques 
(Bennett et al., 1965), amino acid sequencing (Köhler et al., 
1970; Gray et al., 1967), röntgen diffraction analysis (Kabat and 
Tai Te Wu, 1972) and affinity labelling (Fleet et al., 1969; 
Givol, 1974) has provided more insight into the variability of 
structures of the active sites of the immunoglobulin molecules. 
It was demonstrated by Awdeh et al. (1970) that heterogeneity 
may be the result of postsynthetic alterations in the immunoglobu-
lin molecules. They showed that, under the influence of the pH in 
the serum, charge differences can appear in an originally mono-
clonal myeloma protein population, leading to a progressive loss 
of labile amide groups from immunoglobulin molecules. Although 
these postsynthetic changes in structure may partly account for the 
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heterogeneity, it is generally accepted that the greater part of 
this heterogeneity must be ascribed to the development of a mul­
tiplicity of antibody producing cell clones (Askonas et al., 1970). 
Factors that can influence the structure and thereby the 
physicochemical behaviour of the immunoglobulin molecules are: 
properties of the antigen (e.g. electric charge), immunization 
scheme, use of adjuvants, age of immunized animals, site of anti­
body formation and pooling and storage of immune sera (Fahey, 
1962a; Sela and Mozes, 1966; Cramer and Braun, 1974; Mozes and 
Sela, 1969). Although heterogeneity is a characteristic property 
of all immunoglobulins, the degree of this variability is clearly 
dependent on species (Fahey, 1967). Especially in the mouse this 
group of proteins is extremely heterogeneous. 
Thus, structural factors predominant in the variable regions, 
clearly distinct from the class and subclass determining struc­
tures of the heavy chains, have great influence on the physico-
chemical properties of the immunoglobulin molecule. It might, 
therefore, be expected that it will be extremely difficult, if 
not impossible, to separate classes and subclasses of antibodies 
with physicochemical separation techniques. 
IMMUNOGLOBULINS OF THE MOUSE 
The availability of many myeloma proteins and the presence 
of highly inbred mouse strains rendered it possible to study the 
mouse immunoglobulins extensively. The monoclonal character of 
the myelomas made it relatively easy to study the structure of the 
variable as well as the constant parts of the antibody molecules. 
The genetically identical strains have promoted research on many 
genetic and biological aspects of antibody production in repro­
ducible models. Strain influences on the antibody response (Fink 
and Quinn, 1953; Barth et al., 1965), the effect of different pro­
cedures of immunization (Barth et al., 1965; Сое, 1966) and the 
role of metabolic properties of the different immunoglobulin 
classes and subclasses (Fahey and Sell, 1965) could be studied in 
this way. For these very reasons, the mouse may be a preferable 
model for the experimental research of immunoglobulins. 
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In mice, the following classes and subclasses have been iden­
tified: IgM; IgA; IgGl; IgG2a; IgG2b and IgG3 (Fahey and Humphrey, 
1962; Fahey et al., 1964a; Fahey et al., 1964b; Grey et al., 1971). 
Besides their specific antigenic properties, on the basis of which 
they are distinguished in classes and subclasses, they have some 
differences m physicochemical characteristics (Table I). 
TABLE I 
Physiaochenrical properties of mouse immunoglobulin (sub)alasses 
IgM IgA IgGl IgG2a IgG2b IgG3 
molecular weight 900.000 160.000 150.000 150.000 150.000 150.000 
(monomer) 
sedimentation 
coefficient 18S 7-13S 7S 7S 7S 7Ξ 
electrophoretic 
mobility mid γ fast slow slow slow 
anodal γ cathodal γ cathodal γ cathodal γ 
TRANSPLANTATION BIOLOGICAL ACTIVITY OF CLASSES AND SUBCLASSES 
The transplantation biological activities of the immunoglobu­
lins of the mouse have been studied by many investigators. 
Especially the potential of antibodies to destroy (rejection) or, 
alternatively, to protect (enhancement) grafts has been extensive­
ly evaluated. There is, however, no unanimity concerning the in­
fluence of these (sub)classes on the survival of grafts. A com­
pilation of data reported in the literature, authors, techniques 
used for the isolation of the different (sub)classes, transplan­
tation models and effects on graft survival is given in Table II. 
It can be seen from this table how the results reported are con­
fusing and often contradictory. This may be due to differences in 
experimental protocols and procedures. But the most likely reason 
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TABLE II 
Transplantation biological activities of mouse irmunoglobulin (sub)classes 
Author(s) Separation Transplantation Enhancing Destructive or growth 
techniques model activity inhibiting activity 
Bubenik et gel filtration fibrosarcoma 7S and 19S 7S and 19S 
al. (1965) (7S > 19S) (19S > 7S) 
1) 2) Voisin et electrophoresis sarcoma I fast γ globulin n.d. 
al. (1966) 
Moller gel filtration sarcoma 7s n.d. 
(1966) 2-mercaptoetha-
nol-reduction 
Irvin et al.'gel filtration EL4 leukemia 7S γ2 n.d. 
(1967) zone-electro-
phoresis 
Tokuda and starch block sarcoma I serum: fast γ glob. n.d. 
McEntee electrophoresis ascites: fast + slow 
(1967) DEAE-chromato- γ glob. 
graphy 
Chard (196Θ) DEAE-chromato- EL4 leukemia fast γ glob. slow γ glob. 
graphy 
Cruse (1968) gel filtration fibrosarcoma 7S γ2 n.d. 
column electro­
phoresis 
Voisin et curtain and sarcoma I 
al. (1969) block electro­
phoresis 
7S γΐ, IgA 7S γ2 
7S γ2 (in low (in high con-
concentration) centration) 
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Continuation: 
Authorts) Separation Transplantation Enhancing Destructive or growth 
techniques model activity inhibiting activity 
Takasugi and gel filtration sarcoma I 7S γ2 IgM 
Hildemann DEAE- and CM-
(1969a) chromatography 
Takasugi and gel filtration sarcoma I 7S γ2 IgM 
Hildemann DEAE- and CM-
(1969b) chromatography 
Takasugi and gel filtration sarcoma 7S y2 and 7S yl n.d. 
Klein (1971) DEAE- and CM- (γ2 > γΐ) 
chromatography 
Kinsky et al. DEAE chromato- sarcoma I 7S γΐ (?) 7S y2 
(1972) graphy 
Cruse et al. gel filtration sarcoma 7S y2 n.d. 
(1972) DEAE-chromato-
graphy 
Harris and immune absorp- skin 7S γΐ n.d. 
Harris (1973) tion 
Fuller and gel filtration sarcoma I IgM, 7S y2a n.d. 
Winn (1973) immune absorp- 7S у2Ъ 
tion 
Eustace and immune absorp- EL4 leukemia 7S у2а n.d. 
Irvin (1973) tion 
Yutoku et al. gel filtration plasmocytoma IgM, IgG n.d. 
(1974) 
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Continuation: 
Author(s) Separation Transplantation Enhancing Destructive or growth 
techniques model activity inhibiting activity 
Rubinstein et gel filtration sarcoma I IgM (low dosis) IgM (high dosis) 
al. (1974) electrophoresis IgG (low dosis) 7S Y2(high dosis) 
DEAE-chromato- (7Ξ γΐ and 7S γ2) 
graphy 
In earlier investigations, antisera were fractionated by electrophoresis and 
separated in slow and fast γ globulin fractions. With regard to IgG it is 
now known that the fast γ globulin fractions contain mainly 7S γΐ, while the 
slow fractions contain mainly 7S γ2. 
n.d.: not done. 
accounting for this seems to be the fact that most authors used 
physicochemical separation procedures. As already mentioned, it is 
highly unlikely that pure classes and subclasses can be obtained 
by means of these techniques. The samples probably remain contami­
nated with minor quantities of other (sub)classes, and these con-
taihinations may be expected to influence the ultimate effect on 
graft survival. This holds especially for the enhancement experi­
ments, since enhancing antibodies are known to act in minute 
amounts. 
One of the theories forwarded to explain the mechanisms of 
enhancement implied that antibodies responsible for this phenomenon 
could not fix complement and, consequently, had a blocking in stead 
of a destructive effect on the graft. It is known that some immuno­
globulin subclasses are non-complement binding and it is therefore 
not surprising that much of the enhancement research in the last 
few years has dealt with the isolation of classes and subclasses. 
The results of experiments carried out in our laboratory (Koene 
et al.,1973) make it very likely that complement plays an important 
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role in acute antibody-mediated skin graft destruction in the 
mouse. In this species complement activating properties are only 
present in the IgM and IgG2 (IgG2a as well as IgG2b) immunoglobu-
lins. IgA, IgGl and IgG3 do not activate complement. 
In our own attempts to separate immunoglobulin (sub)classes 
we found that the procedure used is very important and we shall 
therefore briefly review here the available techniques pertinent 
to our study. 
SEPARATION OF IMMUNOGLOBULINS 
Conventional separation procedures 
Conventional procedures for the separation of immunoglobulins 
make use of differences in physicochemical properties of these 
proteins. With gel filtration it is possible to separate molecules 
on the basis of their size. With the different electrophoresis 
techniques and with ion exchange chromatography molecules can be 
isolated on the basis of electric charge. With regard to the 
classes and the subclasses of immunoglobulins of the mouse it is 
possible to separate IgM and IgG that differ in size. However, 
the presence of IgA, occurring in different oligomeric forms and, 
therefore, resembling IgM as well as IgG in size, makes an uncon-
taminated isolation of these classes by means of this technique 
illusory. The great heterogeneity in electric behaviour of the 
IgG subclasses, as mentioned in the preceeding section, makes it 
impossible to isolate on this basis, pure and uncontaminated sub-
classes . 
Immunochemical separation procedures 
In immunochemical procedures for the isolation of the immuno-
globulin classes and subclasses, use is made of the specific 
binding of the antibodies to the specific class and subclass de-
termining antigenic structures on the immunoglobulin molecules. 
For years it has been known that by absorption, specific (sub-
classes can be removed out of a mixture of proteins. A new approach 
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in this field is the use of insolubilized antibodies. This insolu-
bilization can be obtained in several ways. The antibodies can be 
polymerized for example with glutaraldehyde (Avrameas and Ternynck, 
1969), and it is also possible to bind them covalently with an 
insoluble and inert carrier substance , such as cellulose or dex-
tran dérivâtes (Cuatrecasas, 1972). By the specific binding of 
the insoluble antibodies with the antigen (in this case, the class 
and subclass determining antigenic structures on the immunoglobu-
lin molecules), it is possible to isolate these (sub)classes out 
of a mixture of proteins. This may occur in a batchwise or in a 
column chromatographic procedure. After initial adsorption of the 
specific (sub)class to the antibody carrying insoluble matrix, the 
non-covalently bound contaminating proteins are removed from the 
matrix by extensive washing. Elution of the specific (sub)class 
molecules may be achieved by lowering the pH or by application of 
concentrated salt solutions. In this way uncontaminated populations 
of antibodies can be obtained. 
Although the use of these specific immune adsorbents seems 
to be an ideal tool for the isolation of pure classes and sub-
classes of immunoglobulins, many practical problems present them-
selves (van Munster, 1972). The use of immunologically monospeci-
fic immune adsorbents is required. If for their preparation one 
starts from polyvalent antisera, made monospecific by adsorption 
with other antigens, soluble antigen-antibody complexes may be 
present in the "specific immune adsorbent" thus obtained. These 
complexes can dissociate during the elution procedures, after 
which they can function as contaminating adsorption sites. 
The adsorption capacity is, in many instances, very small. 
Possible causes for this are a) destruction of the tertiary and 
quaternary structure of the immunoglobulins during the coupling 
procedure, resulting in loss of binding capacity, b) coupling of 
amino groups on the active sites to the carrier which also gives 
rise to loss of binding capacity, c) loss of coupled antibodies 
during the elution procedure. Another problem arises from the 
lowering of the pH during the elution cycle. This may cause a loss 
of biologic activity of the protein to be isolated. The frequently 
observed very small adsorption capacity of the immune adsorbents 
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used for the isolation of pure classes and subclasses of anti-
bodies forms in fact the most important obstacle for a practical 
use of this technique. 
METHODS USED FOR THE ISOLATION OF MOUSE IgG SUBCLASSES IN OUR 
EXPERIMENTS 
As stated above data in the literature suggest that separa-
tion of mouse immunoglobulins by physicochemical methods results 
in some instances in fractions with a different biological acti-
vity on the grafts. Moreover, it was reported by some authors 
that in this way highly purified samples of immunoglobulin classes 
and subclasses could be obtained. Therefore, the initial experi-
ments reported in chapter IV refer to this way of isolation. As 
depicted in figure 2, the complete alloantiserum (B6AF1 anti 
B10.D2 ascites fluid) was first fractionated by gel filtration. 
The 7S fraction obtained in this way was further separated by ion 
exchange chromatography. By this method, five physicochemically 
separated and uncontaminated fractions were obtained, which could 
be tested with respect to their biological activity on the grafts 
in our transplantation model. Chapter V describes the attempts to 
separate IgG into its subclasses by an immunochemical approach. 
As depicted in figure 2 also a first separation with gel filtra-
tion was carried out. Thereafter, the 7S fraction was further 
fractionated with affinity chromatography. 
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B6AF1 anti B10.D2 ascites fluid 
gel filtration (Bio-gel A 0.5 m) 
7S fraction 
cation-exchange chromatography affinity chromatography 
physicochemical separated 
fractions 
IgG subclasses 
1. in vitro cytotoxic activity 
(Chapter IV) 2 . in vivo a c t i v i t y on g r a f t 
s u r v i v a l 
(Chapter V) 
Figure 2: F rac t iona t ion protocol of B6AF1 a n t i B10.D2 a l loant iserum 
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Chapter III 
TRANSPLANTATION GENETICS 
INTRODUCTION 
It is well-known that the fate of grafts is strongly in-
fluenced by genetic factors. Progressive growth of tumor grafts 
or permanent acceptance of normal tissue grafts are in most in-
stances, only possible if antigenic structures on the cell sur-
face, which are called histocompatibility antigens, are identical 
in the donor and in the graft recipient. If they are different, 
or in other words, if the recipient recognizes these histocompa-
tibility antigens as "foreign", then rejection of the graft will 
occur. These histocompatibility antigens, also called transplan-
tation antigens, are determined by histocompatibility genes. These 
genes are located in distinct sites on the chromosomes. These 
sites are called histocompatibility loci (H-loci). 
In transplantation research, the mouse is in many experiments 
a preferable animal model, owing to the availability of highly 
inbred strains, of which the genetic structures have been exten-
sively studied. Congenie strains are strains that are identical 
in genetic constellation except for a small chromosomal segment. 
Many congenie mouse strains are known, in which the genetic 
difference is confined to the histocompatibility locus. With such 
congenie strains it has been possible to study these histocompa-
tibility loci and the transplantation antigens determined by the 
histocompatibility loci. We know from this sort of experiments 
that in the mouse there are probably about 30 histocompatibility 
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loci (Iványi, 1970; Klein, 1973a). There is much evidence that 
each biological species has only one strong histocompatibility 
chromosomal region, which is called the major histocompatibility 
complex (M.H.C.). Apart from that complex a considerable number 
of weaker histocompatibility loci occur. The major histocompati-
bility complex codes for the strong histocompatibility or trans-
plantation antigens. Incompatibility for these antigens represents 
such a strong immunologic barrier that, in the case of skin grafts 
in the mouse, a graft survival t¿me of 15 days is hardly ever 
exceeded. In the mouse this major histocompatibility complex is 
called the H-2 locus. The other minor histocompatibility loci are 
called non H-2 loci and code for weak transplantation antigens, 
inducing weak rejection processes characterized by chronic des-
truction of the grafts, with survival times between 15-300 days. 
In the experiments reported in this study, congenie strains 
differing only at the H-2 locus were used. Therefore the dis-
cussion will be confined to the H-2 system. Data on this subject 
were mostly derived from the extensive reviews of Snell and 
Stimpfling (1966), Iványi (1970), Demant (1973b), Snell et al. 
(1973), Klein et al. (1974c) and Shreffler and David (1975). 
THE H-2 SYSTEM 
The H-2 system comprises a number of closely linked genes 
which are located on the IXth linkage group, which is arranged 
on the 17th chromosome. The term H-2 is derived from a cellular 
antigen (antigen II), originally discovered by Peter Gorer. He 
demonstrated that it was involved in the transplantation process 
by its ability to specifically bind antibodies, formed after the 
grafting of a tumor. After Gorer's experiments the role of the 
H-2 system in the formation of a diversity of serologically de-
tectable cell surface structures and histocompatibility antigens 
could be demonstrated in an increasing number of experiments. 
Recent data demonstrate that the H-2 system comprises not 
only genes determining serologically detectable cell membrane 
structures and transplantation antigens, but also genes inducing 
the capacity for other immunological and non-immunological pheno-
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mena. The particular finding that this complex of genes determines 
such a diversity of traits, has centered renewed interest upon 
this chromosomal region. According to literature the following 
traits are: 
- serologically detectable cellular alloantigens 
- transplantation (histocompatibility) antigens 
- Ir-region lymphocyte alloantigens 
- cell-mediated lymphocytolysis target antigens 
- immune responsiveness to a variety of antigens 
- activity in mixed leucocyte reaction 
- graft versus host reaction 
- production of some serum proteins 
- serum complement levels 
- Τ cell - В cell interaction 
- resistance and susceptibility to oncogenic viruses 
- plasma testosterone levels. 
It is not certain whether all the traits are determined by dif­
ferent genes and at least some of them are probably the manifes­
tations of one single gene. It is assumed, for instance, that the 
serologically detectable cellular H-2 alloantigens and the cell-
mediated lymphocytolysis target antigens are in fact the same 
structures determined by the same gene, but detected with different 
methods (Shreffler and David, 1975) . 
The H-2 genes are linearly arranged on the chromosomal seg­
ment. This makes it possible that crossing-over occurs with the 
analogous segment of the corresponding chromosome. The frequency 
of these crossing-overs between the two ends of the H-2 complex 
amounts to 0.5%. The occurrence of crossing-over resulting in the 
formation of recombinant strains, has made it possible to divide 
the H-2 complex in distinct regions, subregions and loci (figure 
1). These may be defined as follows (Klein et al., 1974c): 
An Η-B region is a segment of the H~2 complex delimited by recom­
bination and consisting of a marker gene and an undeterminate 
number of neighbouring loci. So the H-2 complex can be divided 
into four regions: K, I, S and D, from which the marker genes are 
respectively, H-2K, Ir-IA, Ss and H-2D. These markers will be dis-
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cussed in the following paragraphs. Subregions of a given region 
are segments identified by distinct but functionally related mar­
ker genes and separated from each other and the other regions by 
recombination. So the I region can be divided into three subregions 
Ir-IA, Ir-IB and I-1C. Every region and subregion contains at 
least one locus that can be defined as a segment of the genetic 
material coding for a single polypeptide chain. 
ι H-2 complex I 
Regions К I S D 
ι 1 ι ι ι ι ι 1 
Subregions Ir-IA Ir-IB I-1C 
ι ι ι ι ι ι 
marker loci H-2k Ir-IA Ir-IB la Ss-Slp H-2D 
Figure 1. Genetic map of the H-2 complex of the mouse demonstrating the dis­
tinct regions, subregions and the appropriate marker loci. 
The genetic structure of the regions and subregions of many 
inbred mouse strains could be characterized using the different 
markers. The alternate forms of a gene may be termed alleles, the 
alternate forms of a whole H-2 complex, i.e. the specific combi­
nation of all alleles on the different loci, are called haplo-
types. So far, six standard and independent haplotypes are known 
in inbred mice (Shreffler and David, 1975) . They are designated: 
H-2b, H-2ä, H-2f, H-2k, H-2q, and H-2S. Many other haplotypes, 
originally considered as independent, are now regarded as recom-
binations or mutants of the six standard haplotypes. A growing 
list of these recombinant and mutant strains is becoming available. 
For a detailed description we refer to Klein (1973a) and Shreffler 
and David (1975). 
The availability of such recombinant strains has opened new 
prospects for the study of the distinct regions and subregions of 
the H-2 complex. The contribution of parts of the chromosomal 
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segment to the different traits could be studied more success­
fully by using combinations of mouse strains differing only in a 
given (sub)region. The properties of the different segments thus 
obtained are summarized in the following paragraphs. 
THE К AND D REGION 
Initially, the classification of the H-2 system was based on 
serologically detectable antigenic differences between inbred 
mouse strains. It was assumed that these antigenic specificities 
were determined by multiple genes which were arranged in six 
genetic regions - K, A, E, V, С and D - of the H-2 complex. Later 
studies made it likely that there existed two closely linked loci, 
containing genes coding for the serologically detectable anti­
genic specificities. These regions were called К and D. It is 
hypothesized that they originate from one region by duplication 
(Shreffler et al., 1971). This duplication and the mutational al­
terations occurring at the same time would be responsible for the 
great variety of serologically detectable antigenic cell surface 
structures: more than fifty antigenic differences are known. The 
antigenic specificities can be divided into private specificities 
and public specificities (Snell et al., 1973). The private spe­
cificities are non-recombinant haplotype specific. The alleles 
coding for these private specificities are localized in the К or 
in the D region. The public specificities are not haplotype spe­
cific. They are determined by alleles which may be localized in 
both the К and D region. It is possible that the public specifici­
ties represent cross reacting antigenic determinants determinen 
by the same alleles as those determining the private antigens. 
However, the possibility of distinct but very closely linked ge­
netic sites cannot be ruled out. Public specificities can further 
be divided into short and long public specificities. Short public 
specificities are found in no more than three haplotypes. If they 
are present in more haplotypes, they are called long public spe­
cificities. All these data of the antigenic constellation of the 
different haplotypes are given in the H-2 chart, which is updated 
at regular intervals (Demant, 1973b). 
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The function of the К and D region is not confined to the 
formation of serologically defined antigenic structures. They also 
code for the strong histocompatibility or transplantation antigens 
(Demant et al., 1971a). It is very likely that these latter anti­
gens are identical to the serologically defined antigens, but 
there is not yet definitive proof for this assumption. Further­
more, the К and D regions code for the target antigens for the 
cell-mediated lymphocytolysis. Again, it is possible that the cell 
membrane structures which form the targets for the killing phase 
of the immune response, are the same as the serologically defined 
antigens. 
The involvement of these regions in traits as the mixed leuco­
cyte culture reactivity and the graft versus host reaction is less 
certain. Although there are reports in the literature that the 
К and D regions have some influence on these reactions (Klein et 
al., 1974b; Rychlíková et al., 1971; Alter and Bach, 1974; Demant, 
1971b), there are recent data which support the opinion that the 
I region plays a major role in these processes. This will be dis-
cussed in the following paragraphs. Up till now there is no una-
nimity about the degree of influence that both regions have on 
these traits. 
THE S REGION 
The S region takes the central position in the H-2 complex. 
This' region contains genes that control the levels of the Ss pro-
tein and the Sip protein. The Ss (serum serological) protein is a 
serum ß-globulin, that can be detected serologically by immuno-
diffusion, using heteroimmune antisera. Quantitative differences 
of the serum levels can be distinguished in Ss-H (high) and Ss-L 
(low), corresponding with the alleles Ss and Ss . The sex-limited 
protein (Sip) can be detected on immunodiffusion with alloantisera. 
These alloantisera can be produced by immunization of Sip nega-
tive mice, with the Ss protein of Sip positive mice. The presence 
of the Sip protein is controlled by a gene which is called Sip , 
the absence corresponds with Sip . Under normal conditions this 
protein is only present in males, but it can be induced by the 
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administration of androgens also in females carrying the Slpa gene. 
The biologic functions of these proteins is not clear. It has been 
intriguing that these genes, which are so closely linked to the 
MHC complex, apparently were not directly involved in the immune 
response. Recently, however, Demant et al. (1973a) found that this 
region controls serum levels of hemolytic complement. No other 
influences on histocompatibility reactions, immune responses or 
other alloimmune processes are known. Although the function of the 
S region is unclear, its presence in the H-2 complex has turned 
out to be important, because the easily detectable genetic markers 
have made it possible to establish the cross over positions of 
many recombinant haplotype strains. 
THE I REGION 
The genetic control of the immune response to a variety of 
antigens appears to be determined by dominant genes which were 
closely linked to the H-2 complex. So, the immune response to a 
number of synthetic polypeptides was controlled by a gene that was 
located between the К and the S region of this complex. This was 
located in a region called the "immune response-1" region (Ir-1) . 
Furthermore, it was shown that the response to specitic myeloma 
IgA and IgG proteins, was controlled by genes within this region. 
In different recombinant strains, the alleles, coding for these 
traits appeared to occur separately. In this way the I region 
could be subdivided into Ir-IA and Ir-IB. 
It is not known how the H-2 linked immune response genes 
exert their function. Benacerraf and McDevitt (1972) supposed that 
the Ir genes were coding in some way for a Τ cell receptor and 
this was supported by the findings of Lonai and McDevitt (1974a). 
By others an influence of these genes on В cells was demonstrated. 
Dickler and Sacks (1974) advocated the theory that the Fc receptor 
was determined by these Ir-region genes. The experiments of Katz 
et al. (1973) demonstrate that the cooperation and interaction of 
Τ and В cells is controlled by genetic structures, localized in 
the I region. Although the exact mechanism is unknown, it is likely 
that genes in this region play an important role in alloimmune 
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Variant Traits H-2 complex 
К Ir-lA Ir-lB I-1C 
Serologically detected 
H-2 antigens I 
Transplantation antigens I 
CML target antigens I 
Mixed leucocyte reaction I 
graft versus host reactionl 
Immune responses | 
Ss protein 
Complement levels 
la-lymphocyte antigens 
Figure 2. Map of the H-2 complex and the probable locations of genes control­
ling the variant traits adapted from Shreffier and David (1975) . 
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responses in transplantation. Recent data in the literature show 
that genes localized in the I-region play a predominant role in 
the determination of cell surface structures responsible for the 
mixed leucocyte reaction and the graft versus host reaction (Bach, 
1973; Livnat et al., 1973; Klein and Park, 1973b; Garrison and 
Fathman et al., 1974). Another important finding is the histocom­
patibility function of this I region. Although it was accepted 
that only the К and D regions contained genes coding for histo­
compatibility antigens, an Ir-associated histocompatibility gene 
could recently be detected (Klein et al., 1974a). Possibly cohe­
rent with the immune response function, the resistance or suscep­
tibility to a number of oncogenic viruses is reported to be under 
control of this I region (Lilly, 1972) . Most recently it was de­
monstrated that genes from the I region were able to give rise to 
serologically detectable cell surface structures, predominantly 
expressed on lymphocytes. These antigenic structures were called 
Ir-region-associated (la) antigens. Recombination studies showed 
that the coding genes (alleles) responsible for this could be lo­
calized in the Ir-IA and the Ir-IB subregions, but also in a 
region between Ir-IB and S. This subregion was called I-1C. Because 
of the relevance of this la-antigenic system for our experiments, 
this system will be discussed separately in a following paragraph. 
It is not known, whether the above mentioned traits such as 
immune responsiveness, graft versus host reaction, mixed leucocyte 
reaction, Τ cell - В cell interaction and the la-antigens, are 
experimental representations of only one gene or the products of 
different and distinct genes. A close relation, however, is sup­
posed. 
A schematic survey of the regions and subregions and the 
different traits they code for is depicted in figure 2. 
THE la-ANTIGEN SYSTEM 
As reported in the foregoing paragraphs, the most characteris­
tic trait of the К and the D region was the determination of anti­
genic cell surface structures, which were predominantly detectable 
by serological methods. On the contrary, the I region comprised 
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genes that mainly coded for antigens which could be detected by 
methods measuring the proliferation and activity of lymphocytes. 
For this reason the chromosomal segments of the H-2 complex were 
divided into respectively SD (serologically defined) and LD 
(lymphocyte defined) loci (Bach, 1973). 
Recent data from experiments of David et al. (1973), Sachs 
and Cone (1973), Hauptfeld et al. (1973), Hauptfeld et al. (1974), 
Härranerling et al. (1974), Klein et al. (1974) and Frelinger et al. 
(1974) showed, however, that genes located in the I region could 
also be responsible for the determination of antigenic cell sur-
face structures which could be detected serologically. These anti-
gens were called Ir-region associated (la) antigens. 
Using strains differing only in the central regions (I and 
S) of the H-2 complex, A.T1 and A.TH (genotype KsIkSkDd and 
KsIsSsDd) David et al. (1973) were the first to describe the for-
mation of antibodies directed against antigenic structures deter-
mined by the I region genes. After this initial report, many in-
vestigators have confirmed this finding and a growing number of 
la antigens has been detected. It was a characteristic finding 
in all these experiments that the antibodies directed against la 
antigens showed cytotoxic activity against only part of the lym-
phocytes (about 50% in most cases). Moreover, it was ascertained 
that these la antigens were neither demonstrable on kidney, liver 
and brain tissue (David et al., 1973) nor on muscles or skin epi-
dermal cells (Hauptfeld et al., 1974). So these la antigens could 
be clearly distinguished from the К and D region determined anti­
gens, which show a much wider tissue distribution. The function 
of the la antigens is not clear. It seems attractive to assume 
that these antigens are identical with the LD determinants res­
ponsible for the induction of many cellular immune processes. 
Although there may be some evidence for this hypothesis (Garrison 
Fathman et al., 1974) it is not possible to confirm it without 
the help of further biochemical characterization of these struc­
tures. Further support for the postulate that these la antigens 
are involved in the cellular immune response, is the fact that 
they are predominantly present on lymphocytes. Although, in that 
case it might be expected that they should be present on Τ cells, 
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they were detected in most cases on В cells (Hämmerling et al., 
1974; Klein et al., 1974a; Hauptfeld et al., 1973). Recent experi-
ments, however, which made use of more sensitive cytotoxicity 
tests, have made it very likely that la antigens are present on 
both В cells and Τ cells (Frelinger et al., 1974). This is also 
supported by the findings of Lonai and McDevitt (1974b). It is now 
supposed that there are specific Τ cell la antigens and specific 
В cell la antigens which are probably involved in the specific 
Τ and В cell functions. 
Just as the К and D regions, the I region also contains 
alleles coding for several antigenic specificities. The original 
terms for the single la specificities (Lna; David et al., 1973; 
β; Sachs and Cone, 1973; Ir-1.1; Hauptfeld et al., 1973) were re­
placed by a new terminology (Shreffier et al., 1974), according 
to which they are called Ia-1, Ia-2, Ia-3, etc. 
TABLE I. Distribution of la-specificities among the independent haplotypes 
la-specificities 
Haplotype 
1 2 3 4 5 6 7 8 9 10 
H-2b _ _ з _ _ _ _ 8 9 -
H-2d _ _ _ _ _ 6 7 8 - -
H-2f i - . - s - - - - -
H-2k 1 2 3 - - - 7 - - -
H-2q - - 3 - 5 - - - 9 10 
H-2S _ _ _ 4 5 _ - _ 9 -
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The study of the la-system in different recombinant strains 
- very incomplete as yet - has led to the recognition of 10 la-
specificities. Their distribution among the six independent stan­
dard haplotypes is given in table I. The positions of these known 
la-specificities in the I region, as they could be detected in a 
limited number of recombination strain experiments are depicted 
in figure 3. 
Ir-IA Ir-IB I-1C 
— 1 , 2, 8, 9- 5, 6, 7-* 
10· 
Figure 3. Probable location of the alleles responsible for the different 
la-antigenic specificities, in the I region (adapted from 
Shreffler and David, 1975). 
THE H-2 COMPLEX AND THE TRANSPLANTATION REACTION 
The role of the H-2 complex in the transplantation reaction 
is clearly known and its major histocompatibility function could 
be demonstrated in many animal experiments. The contribution of 
the different and distinct subregions to this complexity of immune 
events is, however, far from completely solved. So far, a histo­
compatibility function could be demonstrated for the К and D 
regions (Demant and Graff, 1973c) and for the I region (Klein et 
al., 1974). Hitherto, no influence on the rejection process is 
known for the S region. 
New insights in the whole array of immune reactions occurring 
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in the transplantation process have resulted from experiments 
studying the functions of the distinct H-2 subregions on what is 
assumed to be the in vitro correlates of the allograft reaction. 
These are the mixed leucocyte reaction and the cell-mediated 
lymphocytolysis. It is hypothesized that for the afferent arc, i.e. 
the sensitizing phase of the immune response, antigens determined 
by genes from the I region, are responsible, while the efferent 
arc, i.e. the killing phase of the immune response, is directed 
against К and D region determined antigens (Bach, 1973; Davies 
and Alkins, 1974). Bach postulated that the initial recognition 
of LD antigens, which might be la antigens, should give rise to a 
proliferation of Τ cells. This Τ cell proliferation might be fol­
lowed by a second response of a population of lymphocytes (T or В 
cells) that are directed against the SD products of the К and D 
regions. 
This hypothesis is interesting in view of recent data of 
Davies and Alkins (1974) and of Staines et al. (1974) who demon­
strated that antibodies which were probably directed against la 
antigens resulted in prolongations of graft survival. They assumed 
that these antibodies prevented graft rejection by blocking anti­
gen recognition, thus acting in the afferent arc of the immune 
response. Although this hypothesis looks very attractive, one 
should realize that up till now the results of in vivo experiments 
are insufficient to support full evidence for this postulate, and 
more investigations will be needed to furnish a complete under­
standing of the rejection reaction. 
GENETIC CONSTELLATION OF THE STRAINS USED IN THE EXPERIMENTS 
The aim of the initial work in our laboratory was to study 
the phenomena of enhancement and graft destruction in a combina­
tion of mouse strains, which only differed in a single strong pri­
vate antigenic specificity. In such a strain combination non-H-2 
differences had to be absent. For this reason the following donor-
recipient combination was chosen. 
Donor strain: B10.D2 (H-2 ) 
Recipient strain: C57BL6/Rij X A/HeJÏF. (H-2 χ H-2a) 
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TABLE II 
Constellation of antigenio speoificitieSj present in the strains of mioe used in the experiments. 
Strain 
B10.D2 
C57BL6/Ry 
A/HeJ 
Haplotype 
H-2 d 
H-2 b 
H-2 a 
Antigenic specificities 
-
-
1 
-
2 
-
3 
-
3 
4 
4 
-
5 
5 
6 
6 
6 
θ 
-
θ 
10 - 13 14 27 
14 27 
10 11 13 14 23 24 25 27 
28 
28 
28 
29 
29 
29 
31 
-
-
33 
34 
-
B10.D2 
C57BL6/Ry 
A/HeJ 
H- 2
d 
Н-2 Ь 
H-2 a 
35 
35 
35 
36 
36 
36 
39 
40 
40 
41 
41 
42 
42 
43 
43 
44 
44 45 
46 
46 
-
47 
47 
49 
49 52 
53 54 56 
These data were obtained from the updated H-2 chart (Demant, 1973) 
4· 
The antigenic constellation of these strains is depicted in Table 
II. From this table it can be seen that in the donor strain only 
two antigenic specificities are present that are absent in the 
recipient strain. These specificities are 31 and 34. Specificity 
31 is a strong private antigen, the determining allei of which is 
localized in the К region of the H-2 haplotype. Specificity 34 
is a new and recently detected antigen. It shows an uneven tissue 
distribution and it seems very likely that 34 is, in fact, not a 
true H-2 specificity but, in fact, an la specificity (Staines et 
al., 1974). 
With regard to the further experiments concerning the study 
of the relationship between enhancement and graft destruction, on 
the one hand, and SD and LD antigenic differences on the other, 
the same strain combination was used. For this we needed a strain 
combination introducing a difference at the К and the I regions. 
Ideally, the BIO.A strain should be used as a recipient because 
this strain not only carries the H-2a haplotype but is also con-
genie with BIO, which eliminates non H-2 differences. The H-2a 
haplotype may be seen as a recombinant strain originating from the 
к d H-2 and H-2 haplotypes, showing a cross-over position in the 
I region. However, we have chosen, for the hybrid B6AF1, since we 
had gained extensive information on passive enhancement in this 
combination and because in this same model hyperacute skin graft 
destruction, too, could easily be induced. The genotypes of the 
donor and the recipient strain are depicted in Table III. 
TABLE III 
Genotype of the H-2 complex of the strains used 
donor B10.D2 
recipient B6AF1 
К 
H-2 d d 
:
b
 χ н - 2 а kb 
H-
Ir- lA 
d 
kb 
-2 complex 
Ir-IB 
d 
kb 
I-1C 
d 
kd 
S 
d 
kd 
D 
d 
kd 
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As can be seen, the strains differ in the К region and in the 
Ir-IA and Ir-IB subregions. Antibodies elicited by cross immuni­
zation can thus only be directed against antigens coded for by 
genes of these (sub)regions. It will be shown that the choice of 
this donor-recipient combination enabled us to detect a new la 
specificity. 
The la antigenic constellation of these mouse strains as far 
as it is known at present is given in table IV. 
TABLE IV 
la speaifiaities present in the strains used in the experiments 
Strain Haplotype la-specificities 
B10.D2 H-2 d 6 7 8 
C57BL6/Ry H-2 3 8 9 
A/HeJ H-2 a 1 2 3 6 7 
From this table it is clear that the donor strain (B10.D2) con­
tains no known la-specificities, that are not represented in the 
recipient strain ((C57BL6/Ry χ A/HeJJFj). However, the list of 
known la antigenic specificities is far from complete, especially 
with regard to the H-2 haplotype (Shreffler and David, 1975). 
Therefore, the results of the experiments to be reported in chap­
ter VI, demonstrating the presence of cytotoxic antibodies that 
are not directed against H-2K antigens, but that show the charac­
teristics of antibodies against la antigens, point to the presence 
in the donor strain of a hitherto unknown la specificity. This 
specificity must be determined by an allei localized in the Ir-IA 
or Ir-IB subregions of this strain. 
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Chapter IV 
ENHANCEMENT AND HYPERACUTE REJECTION OF SKIN 
GRAFTS IN THE MOUSE 
Failure to separate cytotoxic and enhancing 
antibodies from alloantiserum with physico-
chemical methods 
Jan L.J. Jansen, Robert A.P. Koene, Gerard J. van Kamp, 
Paul G.G. Gerlag, and Paul G.A.B. Wijdeveld 
From the Department of Medicine, Division of Nephrology, 
University of Nijmegen, Sint Radboudziekenhuis, Nijmegen, 
The Netherlands 
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B6AF1 anti-BIO.D2 ascites fluid was fractionated by mole-
cular sieving and cation exchange chromatography in an attempt 
to separate cytotoxic and enhancing antibodies. Five fractions 
were obtained which showed no overlap on analysis with isoelec-
tric focusing. Despite this complete physicochemical separation 
all fractions contained detectable amounts of 7S IgGl and 7S 
IgG2. Furthermore, enhancement of B10.D2 skin grafts in B6AF1 
recipients could be induced with all the fractions. Cytotoxic ac-
tivity was also present in the fractions. This was not only 
shown in vitro by the cytolysis of B10.D2 lymphoid cells in the 
presence of rabbit complement, but also by the ability of the 
different fractions to induce hyperacute destruction of B10.D2 
skin grafted onto B6AF1 mice after i.v. injection together with 
rabbit complement. Thus, we were unable to separate the allo-
antiserum in cytotoxic and enhancing fractions by physicochemical 
means. 
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Mouse alloantisera are able to prolong specifically the sur­
vival of skin allografts in certain donor-host combinations, if 
these sera contain antibodies directed against the graft antigens 
(1). This phenomenon is an example of immunologic enhancement. On 
the other hand, these same sera do contain cytotoxic activity as 
they are able to lyse specifically mouse lymphoid cells, in vitro, 
in the presence of an appropriate species of complement. These 
cytotoxic factors are not only demonstrable in ir vitro assays 
but have been shown to be active also in vivo, where they, for 
example, are able to inhibit the growth of allografts of tumors 
under certain conditions (2). Furthermore, we have recently re­
ported the hyperacute destruction of mouse skin grafts by allo-
antiserum in vivo in a donor-host combination comprising a 
limited amount of antigenic differences. Λ prerequisite for the 
occurrence of this reaction was the simultaneous administration 
of an effective complement species (3). 
The mouse is an excellent model for the study of the bio­
logic activity of alloantibody because inbred strains with an 
extensive background of genetic information are available, and 
also because there is a fairly good knowledge of the mouse immu­
noglobulins, with respect to molecular structure and function, 
mainly as a result of the study of myeloma proteins (4-8). The 
results of attempts to separate so-called enhancing and cytotoxic 
antibodies, which are presumed to be present in hyperimmune sera, 
are nevertheless confusing and contradictory. Except for a few 
reports on the role of IgA (9) and IgM (10), most investigations 
point to the IgG 7S globulins as the biologically active fraction. 
Using physicochemical fractionation procedures, e.g., curtain or' 
starch block electrophoresis (9, 11, 12) or ion-exchange chroma­
tography (2, 13-16), some of the investigators (2, 12, 14, 15) 
concluded that the enhancing antibody is of the IgG2 class. By 
contrast, from other studies (9, 11, 13, 16), it was concluded, 
that the enhancing antibody belonged largely to the IgGl class. 
The гп vitro cytotoxic properties of the immunoglobulins are 
always ascribed to the complement fixing 7S IgG2 fraction. 
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An explanation for these apparently contradictory results 
may be that in these studies different transplantation models 
were used. But of more importance seems the fact that many of the 
isolated fractions were contaminated with at least minor quanti-
ties of immunoglobulins of other (sub)classes. This is not sur-
prising since one of the prominent features of the immunoglobu-
lins is their marked heterogeneity in physicochemical behavior 
(17). Even minor contaminations of the different fractions might 
have considerable influence on the eventual outcome of the ex-
periments. It has been shown, for example, that the fate of tumor 
grafts can be dose dependent. Small increases in dosage can in-
duce growth inhibition of a tumor which is easily enhanced by a 
slightly lower dose of antiserum (18). 
A difficulty in interpreting the results of studies with 
skin grafts is that, in vivo, only the capacity to induce en-
hancement could be studied because a reproducible model to 
measure antibody-mediated damage in vivo in the mouse was lacking. 
The hyperacute rejection of skin allografts by antibody and com-
plement, recently reported from this laboratory (3), might serve 
as such a model. This seems of special importance since in the 
same donor-host combination, using essentially the same anti-
serum but without complement, significant prolongation of graft 
survival due to enhancement has been described (19). Thus, we had 
the opportunity to test the destructive and the enhancing capa-
city of an alloantiserum in a single model in vivo. We describe 
in this report our attempts to separate this alloantiserum into 
cytotoxic and enhancing fractions by physicochemical means, and 
the results of experiments that try to correlate biologic acti-
vity with the presence of different IgG classes in the respective 
fractions. 
METHODS 
Animals. 
Inbred lines of B10.D2 (H-2 ) mice were originally obtained 
from the Jackson Laboratory (Bar Harbor, Maine). C57BL6/Rij (H-21 
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and A/HeJ (H-2 ) mice were obtained from the Radiobiological In­
stitute (Rijswijk, the Netherlands). In our animal laboratory, 
these mouse strains were kept by continuous brother-sister 
matings. (C57BL6/Rij χ A/HeJ) F. (= B6AF1) hybrids were raised 
in the laboratory. 
Alloantiserum. 
B6AF1 anti-BIO.D2 serum was prepared by injecting B6AF1 mice 
at weekly intervals, i.p., with a suspension of B10.D2 lymphoid 
cells in complete Freund's adjuvant. After six injections most 
animals developed ascites and could be tapped every 2 weeks. The 
cytotoxic titer of the ascites fluid was the same as the titer in 
the serum of these mice. This antiserum contains antibodies di­
rected against H-2K.31 (19). Sera viere pooled and stored at -20 C. 
Hetero antiserum. 
Goat anti-B6AFl lymphocyte serum (ALS) was prepared by a 
subcutaneous injection of B6AF1 lymphocytes in complete Freund's 
adjuvant into a goat followed by weekly i.V. boosts of B6AF1 
cells. The serum obtained 1 week after the fifth immunization was 
heated at 560C for 45 min. and stored at -20OC. 
Complement. 
Fresh frozen sera (-20 C) from rabbits were used as a source 
of complement. In the dilutions used in the in vitro cytotoxic 
test (1:4) the complement was not toxic to mouse lymphoid cells 
and, therefore, absorptions with mouse cells before use were un­
necessary. 
Fractionation procedures. 
The 19S and 7S antibodies were isolated from the hyperimmune 
Abbreviations used in this paper: ALS, anti-lymphocyte serum; 
IEF, isoelectric focusing; MST, median survival time; S.D., stan­
dard deviation. 
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sera, by Bio-Gel A-O.5 m (Bio-Rad Laboratories, Richmond, Calif.) 
gel filtration in a К 50/100 column (Pharmacia, Uppsala, Sweden) 
at room temperature (equilibrating buffer 0.1 M Tris HCl, 0.2 M 
NaCl, 0.02% NaN,, pH 8.0). A constant flov/ of 78 ml/hr was main­
tained by a pump (Cenco). The fractions were collected at 8-min 
intervals with a LKB collector, and protein content was recorded 
by continuous flow through an Uvicord II absorption photometer, 
which recorded UV transmission at 280 nm. 
Further separation of the 7S fraction was obtained by ion-
exchange chromatography. For this purpose carboxymethyl cellu­
lose (CM-52, Whatman) was expanded in the initial buffer of 
0.010 M phosphate at pH 5.8, and packed in a glass column (60 χ 
1.5 cm). To adjust the 7S antibodies to the initial buffer, they 
were passed through a Sephadex G-25 coarse column (80 χ 2.6 cm) 
equilibrated to this buffer. Thereafter, the sample was applied 
to the ion-exchange column. The portion of the sample that did 
not bind to the column at the initial pH and molarity was labeled 
fraction I. After this fraction had passed the column, the pH was 
raised to 6.1 and a method of stepwise elution was used involving 
seven steps of increasing molarity w:th respect to phosphate 
(0.010 to 0.050 M) . After each step the conductivity of the elu-
ate was measured until an equilibrium was reached. The flow rate 
was kept at 24 ml/hr. All fractions were equilibrated in salt by 
passage through a G-25 coarse column and sterilized by means of 
membrane filtering (Sartonus membranfliter SM 11306, Göttingen, 
West Germany. 
Analytical procedures. 
All the fractions were analyzed by isoelectric focusing 
(IFF) according to a modification of the method of Wngley (20) : 
2.92 ml 1% Ν, Ν, N, N-tetramethyl ethylene diamine, 10.98 ml 
acryl amidebisacrylamide solution, and 1.10 ml ampholyte (pH 3.5 
to 10), were mixed and water was added to a final volume of 45 
ml. After deaeration, 3 ml 1% (w/v) persulfate solution were 
added. Before and after mixing, the solutions were cooled m ice. 
The mixture was poured carefully into glass tubes (150 χ 4 mm). 
60 
After polymerization, a solution of 0.25 ml 40% ampholyte (pH 3.5 
to 10) and 500 mg sucrose in 10 ml of water was layered on top of 
the gels. Up to 100 μΐ of a solution containing 5 mg protein and 
100 mg sucrose m 1.0 ml of water were added. The maximal amount 
of protein applied was thus 0.5 mg. The anodal vessel was filled 
with 0.2% sulfuric acid, the cathodal vessel with 0.4% ethylene-
diamine. Electrofocusing was completed in 6 hr at 500 V. Gels 
were stained with Coomassie Brilliant Blue according to Malik and 
Berne (21). 
Polyacrylamide gel electrophoresis was performed according 
to a modification of Bloemendal's method (22). The gels were 
stained with amido black. The gels were scanned in a Gilford 2000 
scanning spectrophotometer using a slit of 0.2 χ 2.36 mm. The 
areas under each elution pattern were measured with a planimeter. 
Two-dimensional immunodiffusion against specific antisera 
directed to 7S IgGl, 7S IgG2, IgA and IgM (Meloy) was performed 
according to the method of Ouchterlony. For Immunoelectrophoresis 
against rabbit anti-mouse serum (Meloy) the method of Scheidegger 
was used (23). 
Serology. 
The antisera and the different fractions were tested in 
vitro with B10.D2 lymphoid cells by using the trypan blue dye ex­
clusion method (24). Spleen cells were prepared free of red cells 
with Tris-NH4C1 (25). 25 μΐ of cells (5 χ 10
6/ml) were incubated 
in microtiter test plates with equal volumes of antibody dilu­
tions and rabbit complement for 30 min at 370C. The titer was de­
termined as the antiserum dilution giving 50% lysis. All titra­
tions were performed in duplicate. Complete alloantiserum to 
H-2K.31 had a titer of 1:512. 
Skin grafts. 
B10.D2 tail skin was grafted onto B6AF1 recipients by the 
procedure described by Billmgham and Medawar (26). In all experi­
ments donor and recipient were of the same sex. Only mice 6 to 12 
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weeks of age were used. The casts were removed on the 6th day af-
ter transplantation. The fate of the graft was followed daily by 
macroscopic inspection. The median survival times (MST) and the 
standard deviations (S.D.) were calculated by the method of 
Litchfield (27). 
Passive enhancement. 
Male B10.D2 tail skin was grafted onto male B6AF1 recipients. 
On days 0, 2, and 4 after skin grafting the recipient received 
0.25 ml alloantiserum to H-2K.31, or its fractions, i.p. Control 
animals received equal volumes of normal B6AF1 serum. 
Hyperacute rejection. 
Female B10.D2 tail skin was grafted onto female B6AF1 reci-
pients. The experiments were performed on well established grafts. 
The survival of these grafts was prolonged by the injection of 
0.25 ml ALS on days 0, 2, and 4 after transplantation. On day 7 
after grafting, the mice received a single i.v. injection of 0.25 
ml of alloantiserum, or its fractions, and 0.25 ml of rabbit com-
plement. Hemorrhages and necrotic changes in the grafts, within 
24 hr after the injection, were taken as criteria for hyperacute 
rejection (3). 
RESULTS 
Fractionation procedure and analysis of the fractions. 
We found a three peak pattern after molecular sieving of 7.5 
ml of ascites fluid on Bio-Gel A-0.5 m in agreement with other re-
ports (28). The second peak, which contained the 7S fraction, was 
pooled and concentrated by ultrafiltration to a protein content 
of 4 mg/ml. After equilibration of this fraction in the starting 
buffer, a sample containing 60 mg of protein was further separa-
ted by cation-exchange chromatography. Each fraction was then 
analyzed by IEF. Most fractions were shown to be contaminated 
with neighboring fractions. Therefore, repeated chromatography of 
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each fraction up to three times was necessary. By following this 
procedure we eventually obtained five fractions labeled I to V, 
that showed only a very small, if any, overlap as demonstrated by 
IEF (Fig. 1). Only with this technique was it feasible to ana­
lyze properly these fractions. Figure 2 shows that by Polyacryl­
amide gel electrophoresis we were unable to demonstrate a clear-
cut separation of the different fractions since from fraction I 
to V only a slight shift to the top of the gel is visible. The 
results show the superiority of the technique of IEF for the ana­
lysis of these fractions. 
3,5 
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Figure 1. Isoelectric focusing of fractions I to V after re­
peated chromatography on CM52 (see text). There is virtually 
no overlap between the different fractions. 
pH 
G3 
The five fractions thus obtained were further analyzed by 
immunodiffusion against specific antisera. Samples with a protein 
content of 3 mg/ml were tested. When this concentration was used, 
7S IgGl as well as 7S IgG2 could be detected in fractions IT, III, 
and IV. Fractions I and V showed only a precipitation line against 
the anti 7S IgG2 serum, but after a 7-fold concentration of the 
samples, the presence of 7S IgGl could also be demonstrated. The 
overall results are given in Figure 3. This figure also shows 
that only fraction I contained detectable amounts of IgA. Preci­
pitation lines against IgM were absent from all five fractions. 
Immunoelectrophoresis of the concentrated fractions (protein con­
tent 15 mg/ml) gave comparable results. Two precipitation lines 
were present in each fraction, corresponding to 7S IgGl and 7S 
TgG2. It is noteworthy that fron fraction I to fraction V there 
О 
anti 
H-2K 
31 7S IV V 
Θ 
Figure 2. Analysis of the fractions I to V by Polyacrylamide 
gel electrophoresis. There is a gradual shift of the fractions 
to the top of the gel without a clearcut separation. 
0 4 
was a gradual shift of both precipitation lines to the cathodal 
end of the plate but no clearcut separation of the fractions was 
present. This result is in agreement with the results of the Poly­
acrylamide gel electrophoresis (Fig. 2) where also a shift of the 
protein bands to the cathodal end was found. 
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Figure 3. Immunodiffusion of fractions I to V against specific 
antisera. All fractions show precipitation lines against anti-
7Sy1 and anti-7SY2 serum. IgA is only present in fraction I. 
Precipitation lines against IgM are not demonstrable. 
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The results clearly demonstrate that although an almost com-
plete physicochemical separation was obtained, as demonstrated by 
IEF, all fractions contained detectable amounts of 7S IgGl and 7S 
IgG2. It is thus evident that the different IgG subclasses show a 
marked heterogeneity in their physicochemical behaviour and, 
therefore, cannot be separated on this basis. 
Biologic activity of the fractions. 
From our failure to separate immunoglobulin subclasses by 
physicochemical methods it does not necessarily follow that this 
technique would also be inadequate in separating biologic activi-
ties present in the sera. As we mentioned already, several re-
ports in the literature do suggest that it is feasible to sepa-
rate enhancing and cytotoxic factors in this way. In the next 
series of experiments we have, therefore, tested the different 
fractions for their biologic activity. For this purpose fractions 
were reconstituted to a protein content that was equivalent to 
their concentration in whole, undiluted antiserum. This was done 
by scanning the IEF gels of whole serum and of its five fractions 
with a scanning spectrophotometer. The areas under the elution 
patterns of each fraction were measured with a planimeter and 
compared to the corresponding area in whole serum. The protein 
concentrations of the fractions, thus calculated are given in 
Table I. 
A. In vitro cytotoxicity. 
The fractions were tested for their -in vitro cytotoxicity 
with the trypan blue method. The results of the titrations are 
given in Table I. All fractions contained detectable amounts of 
cytotoxic antibody directed against B10.D2 cells, in protein con-
centrations which were equivalent to those present in the complete 
alloantiserum. Fraction I showed only slight cytolysis (up to 
25%) in the first three dilutions, but after a 3-fold concentra-
tion (to a protein content of 1.95 mg/ml), there was definite 
cytotoxic activity demonstrable, the titer being 1:16. 
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Fraction No. 
TABLE I 
Biological activity of antiserum to H-2K.Z1 and its fractions 
Protein Cytotoxic 
Content Titer 
Enhancement' 
No. M.S.Τ.+S.D. 
Destructive Capacity 
No. Hyperacute M.S.T.+S.D. 
rejection 
mg/ml 
Control 
I 
I 
II 
III 
IV 
V 
Anti--H-
s 
2K 31 
0.65 
1.95 
0.52 
1.26 
1.00 
0.82 
0 
0 d 
1:16 
1:16 
1:16 
1:32 
1:128 
1:512 
days 
13.5+1.08 
14.2+1.10 
15.4+1.10 
16.0+1.07 
17.3+1.06 
17.0+1.12 
18.4+1.06 
19.0+1.10 
NS 
<0.02 
<0.003 
<0.005 
<0.003 
<0.005 
<0.003 
11 
6 
5 
5 
5 
5 
5 
10 
-
-
+ 
+ 
+ 
+ 
+ 
+ 
days 
19.8+1.20 
14.2+1.03 
0.25 ml intraperitoneally on days 0, 2, and 4 after grafting. 
Recipients treated with 0.25 ml ALS intraperitoneally on days 0, 2, and 4 after skin 
grafting. 0.25 ml of antiserum or its fractions and 0.2 5 ml of rabbit complement were in­
jected intravenously, on day 7. 
Level of significance (Student's t-test) 
Slight cytolysis (up to 25%) in the first three dilutions. 
В. Passive enhancement. 
The capacities of the different fractions to induce enhance­
ment in B6AF1 mice were tested by injecting 0.25 ml of each frac­
tion on days 0, 2, and 4 after transplantation of a B10.D2 skin 
graft. Control animals received normal B6AF1 serum. The results 
are given in Table I. Whole anti H-2K.31 gave significant pro­
longation (MST 19.0 days). This is in accord with previous fin­
dings in this model (19). Since the unconcentrated fraction I 
showed only slight cytotoxic activity in vitro, we tested this 
fraction in vivo also after concentration of the sample. When the 
fraction was administered unconcentrated, graft survival was not 
significantly different from that of control mice (MST 14.2 and 
13.5 days, respectively). But after a 3-fold concentration signi­
ficant prolongation was demonstrated (MST 15.4 days). All the 
other fractions were able to prolong graft survival in a protein 
concentration equivalent to that present in whole serum. It should 
be noted that for most fractions the degree of prolongation was 
only slightly less than that induced by whole antiserum. 
С Hyperacute rejection. 
Similarly, all fractions were tested for in vivo cytotoxici­
ty by their ability to induce hyperacute rejection after their 
i.v. injection together with rabbit complement. The results are 
summarized in Table!. Hyperacute destruction of the grafts could 
be induced with all fractions. Fraction I had to be concentrated 
three times to give a visible effect. After concentration, how­
ever, all grafts were necrotic within 24 hr after the injection. 
Grafts in control animals showed a MST of 19.8 days. 
Thus, all fractions not only contained enhancing properties, 
but possessed also definite cytotoxic activity in both the in vi­
tro and the in vivo systems. It might be argued that the separa­
tion of the fractions was not complete, since there was still a 
slight overlap between neighboring fractions on IFF (Fig. 1). It 
should be borne in mind, however, that fractions II and V, which 
showed not the slightest overlap, both contained not only 7S IgGl 
68 
and 7S IgG2 but also enhancing as well as cytotoxic activity. 
DISCUSSION 
The results of our experiments shov? a marked heterogeneity 
of the 7S immunoglobulins in their physicochemical behavior. Not 
only did all fractions contain detectable amounts of 7S IgGl and 
7S IgG2, but the antibody specificity directed against H-2K.31 was 
also demonstrable in each fraction. The use of pooled antisera 
may have contributed to this marked heterogeneity (29) but in 
studies of antisera of individual mice we found similar results. 
IEF seems to be the best method available to analyze immune sera 
after ion exchange chromatography. Only with this technique could 
a marked contamination of all fractions after the first chroma-
tographic separation be demonstrated. We thus found that a second 
and a third chromatography were absolutely required to achieve 
optimal separation. Other methods, e.g., Polyacrylamide gel elec-
trophoresis were at least in our hands completely inadequate. It 
is our impression that most investigators of the in vivo effects 
of physicochemically separated fractions of enhancing antisera 
have not fully appreciated the importance of this heterogeneity. 
In cur model and with our techniques we were unable to separate 
antiserum in fractions containing only 7S IgGl or 7S IgG2. 
All fractions showed the capacity to induce significant en-
hancement of B10.D2 skin grafts. These results are in striking 
contrast to those of other groups who ascribed the enhancing ca-
pacity to 7S IgGl on the one hand (11, 9, 13) or 7S IgG2 on the 
other hand (12, 14, 15). We cannot fully explain these completely 
different findings. On the basis of our results it does not seem 
likely that the fractions, obtained in the above mentioned studies, 
have been "pure" 7S IgGl or 7S IgG2. We presume that they were 
contaminated with at least minor amounts of other subclasses of 
immunoglobulins since they were obtained by physicochemical frac-
tionation procedures. Antibody dosage may then determine the 
eventual outcome. The importance of dosage is also illustrated 
by our results with fraction I (Table I). If the fraction was 
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unconcentrated, there was no significant prolongation of skin 
graft survival, but after a 3-fold concentration the MST was sig­
nificantly prolonged. 
All the fractions that could prolong skin graft survival were 
also able to induce hyperacute rejection. We have previously de­
monstrated that whole antiserum is able to destroy the skin graft 
in this model within 24 to 48 hr (3). Histologic examination of 
the grafts shows accumulation of polymorphonuclear granulocytes 
in the skin, which is compatible with an Arthus reaction. There­
fore, we expected that the IgG fraction in the hyperimmune serum 
would be responsible for the occurrence of this phenomenon. That 
this was indeed the case is suggested by the results of the cur­
rent study where IgG was as active in the induction of hyperacute 
rejection as whole antiserum. Our results also show clearly that 
all the fractions contained this destructive capacity. Because 
all fractions contained 7S IgGl as well as 7S IgG2 we were unable 
to decide if the former are enhancing and the latter cytotoxic, 
or if all the activity is confined to only one subclass. It is, 
however, unlikely that 7S IgGl caused the hyperacute rejection 
since this subclass is not complement binding and since the hyper­
acute rejection in our model is clearly a complement-dependent 
phenomenon. This is not only apparent from our own studies, but 
also from the work of Winn et al (30) , who showed that the pre­
sence of a normal complement system was important for the anti­
body-mediated destruction of rat skin grafted onto mice. It might 
be speculated from the results of the study reported here that 
enhancement and hyperacute rejection can both be caused by 7S 
IgG2 since this immunoglobulin subclass is predominantly present 
in the most active fraction. This is in accord with the findings 
of Fuller and Winn (10) who demonstrated that 7S IgG2 and 7S 
ІдС2, subclasses of alloantibody against a fibrosarcoma (Sal), 
obtained by using immunoprecipation with anti-heavy chain reagents, 
could enhance as well as inhibit the growth of Sal in allogeneic 
and syngeneic recipients, respectively. 
Recent studies have made it likely that the antiserum used 
in the model reported here not only contains antibodies directed 
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against the serologically defined H-2K region antigens of the ma-
jor histocompatibility complex in the mouse, but also against 
antigens determined by a region associated to the Ir-region. These 
antigens have been termed la antigens, and they are apparently 
only present on lymphoid cells (31). Furthermore, there is evi-
dence that the products of genes of the Ir region can function 
as transplantation antigens since Klein et al (32) have recently 
shown that skin graft rejection can occur in strain combinations 
that differ only in this region. It is not yet clear whether the 
la antigens and Ir-acsociated transplantation antigens are deter-
mined by identical genes or by genes mapping closely together. In 
any case, these recent findings raise the possibility that anti-
bodies directed against these antigens might play a role in the 
rejection of skin grafts. These antibodies, which are also pre-
sent in the antiserum used in this study, might for example be 
responsible for the enhancement of the skin grafts whereas the 
antibody specificity directed against H-2K.31 might induce the 
hyperacute rejection. 
This hypothesis is reinforced by the findings of Staines et 
al-(33) that the enhancing capacity of an antiserum is retained 
after the removal of H-2 antibodies by absorption with erythro-
cytes. They could show that the remaining antibody activity was 
directed preferentially against B-cell antigens. Analogous results 
were obtained in the rat (34). 
It is clear, however, that it is not possible to obtain a 
separation of the 7S IgGl and 7S IgG2 subclasses of the antiserum 
studied by using physicochemical methods. The same holds for the 
separation of the enhancing and destructive capacity of this se-
rum because all fractions were able to induce enhancement as well 
as hyperacute rejection of a B10.D2 skin graft. A better approach 
to the separation into pure immunoglobulin (sub)classes is the 
use of affinity chromatography with monospecific anti-immunoglo-
bulinsera. The (sub)classes thus obtained should be tested for 
their biologic activity in vitro and in vivo. 
In a second step the biologically active (sub)classes can be 
absorbed with red blood cells to remove antibodies directed against 
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the "classical", serologically defined, H-2 antigens. These stu-
dies might enable us to answer the question whether alloantibodies 
showing a distinct specificity and opposite biologic effects, and 
that are apparently present together in an alloantiserum, do be-
long to the same or to different (sub)classes of immunoglobulins. 
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Chapter V 
ISOLATION OF PURE IgG SUBCLASSES FROM MOUSE 
ALLOANTISERUM AND THEIR ACTIVITY IN ENHANCEMENT AND HYPER-
ACUTE REJECTION OF SKIN ALLOGRAFTS 
Jan L.J. Jansen, Robert A.P. Koene, Gerard J. van Kamp, 
Wim P.M. Tamboer, and Paul G.A.B. Wijdeveld 
From the Department of Medicine, Division of Nephrology, 
University of Nijmegen, Sint Radboudziekenhuis, Nijmegen, 
The Netherlands 
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B6AF1 anti-BIO.D2 ascites fluid was fractionated by mole-
cular sieving. From the 7S fraction, IgG subclasses were isolated 
by affinity chromatography with specific antisera against mouse 
immunoglobulin subclasses coupled to CNBr-activated Sepharose 4B. 
Thus, 7S IgGl , 7S IgG2, 7S IgG2a, and 7S IgG2b were obtained 
which were completely pure by criteria of immunodiffusion and 
immunoelectrophoresis. In the in vitro tests the 7S IgGl complete-
ly lacked cytotoxic activity. All the other subclasses were able 
to induce lysis of B10.D2 cells in the presence of rabbit comple-
ment. 
All subclasses were tested for their capacity to induce en-
hancement and hyperacute destruction of B10.D2 skin grafts in 
B6AF1 recipient mice, and for the dose-dependency of these effects. 
7S IgGl, although showing clearcut enhancing activity, was com-
pletely inactive in inducing hyperacute destruction of the grafts, 
even if high doses were administered. By contrast, 7S IgG2 (IgG2a 
as well as IgG2b) was not only able to induce enhancement but 
also hyperacute destruction of the grafts. The results obtained 
with 7S IgG2 demonstrate that opposite biologic activities can be 
present within a single subclass. 
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The survival of allografts of tumors and of normal tissues 
can be prolonged in different transplantation models by the ad-
ministration of hyperimmune alloantisera, due to the presence in 
these sera of alloantibodies, which specifically block the immune 
response (1, 2). On the other hand, these same antisera can, in 
conjunction with complement, specifically lyse target cells in 
vitro, and these effects are in apparent contradiction to the 
blocking effects in vivo. Moreover, it has been shown that these 
alloantisera can sometimes damage grafts in vivo. Using the C57BL 
leukemia EL4 as a tumor graft Chard could demonstrate significant 
growth inhibition due to the administration of specific alloanti-
serum (3). Similar results were obtained by Yutoku et al. with 
the mouse plasmacytoma X 5563 (4).The findings of Baldamus et al. 
(5) show that normal tissue grafts are also sensitive to the des-
tructive action of antibodies. We recently reported the hyperacute 
rejection of mouse skin grafts after the administration of allo-
antiserum together with an effective species of complement (6). 
This model is of special interest because in the same donor-host 
combination, using the same alloantiserum but without complement, 
a significant prolongation of skin graft survival due to enhance-
ment can be induced (7). The alloantisera apparently contain com-
ponents with an opposite biologic activity and this raises the 
question if it is feasible to isolate these different activities. 
One of the possible procedures is the separation of the 
immunoglobulins into their (sub)classes. Differences in the bio-
logic activities of these subclasses, especially regarding their 
ability to bind complement, do justify a further analysis of the 
transplantation biologic properties of the individual immunoglo-
bulin (sub)classes. 
Since our experiments pointed to a role of complement in the 
induction of hyperacute rejection, only the complement-binding 
IgM and 7S IgG2 antibodies would be the candidates responsible 
for the destructive effect. With regard to the enhancing capaci-
ties of the different (sub)classes of immunoglobulins, the results 
reported in the literature are not uniform, but even contradict-
ory. Apart from a few reports on the role of IgA (8) or IgM (9), 
most experiments point to the 7S IgG antibodies as the enhancing 
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fraction. Especially with regard to the effectiveness of the IgG 
subclasses much confusion exists in the literature. Some of the 
investigators conclude that the enhancing antibody is of the 7S 
IgG2 class (3, 10, 11), and other studies suggest that the en-
hancing activity must be ascribed to the 7S IgGl (8, 12, 13). 
Earlier experiments m this laboratory showed that, starting from 
7S IgG by using cation-exchange chromatography for isolation and 
isoelectric focusing for analysis, several fractions were obtain-
ed that were able to induce enhancement as well as hyperacute 
destruction of mouse skin allografts. In spite of complete physi-
cochemical separation, all fractions contained 7S IgGl as well as 
7S IgG2 although in some instances these contaminations could 
only be demonstrated in highly concentrated samples by immunodif-
fusion or by Immunoelectrophoresis (14). These results led to the 
conclusion that, obviously due to the heterogeneity of the immuno-
globulins (15), physicochemical procedures are not suited for the 
isolation of pure immunoglobulin (sub)classes from mouse serum. 
Therefore, we have attempted to obtain a better purification of 
7S IgG subclasses by means of affinity chromatography. We report 
here the isolation of pure IgG subclasses from the 7S fraction of 
a mouse alloantiserum (B6AF1 anti-B10.D2 ascites fluid). This 
alloantiserum could induce enhancement as well as hyperacute re-
jection of B10.D2 skin allografts in B6AF1 recipients. IgG sub-
classes 7S IgGl, 7S IgG2, 7S IgG2a and 7S IgG2b completely pure 
by criteria of immunodiffusion and Immunoelectrophoresis, could 
be studied for their capacity to cause enhancement and hyper-
acute destruction of the skin grafts. Furthermore, in view of 
reported influences of dose differences (4, 16), we have studied 
the dose-effect relationship of the different subclasses with 
regard to destructive as well as enhancing activity. 
MATERIALS AND METHODS 
Animals. 
Inbred strains B10.D2 n/Sn (H-2 ) mice were originally ob-
tained from the Jackson Laboratory (Bar Harbor, Maine). C57BL6/Rij 
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(H-2 ) and A/HeJ (H-2 ) mice were obtained from the Radiobio­
logical Institute (Rijswijk, The Netherlands). In our animal la­
boratory, these mouse strains were kept by brother-sister matings. 
(C57BL6/Rij χ A/HeJ) Fl (= B6AF1) hybrids were produced in the 
laboratory. 
Alloantiserum. 
Alloantiserum to H-2K.31 was prepared by injecting,i.p., 
B6AF1 mice at weekly intervals with 5 χ 10 B10.D2 lymphoid cells 
obtained from spleen, thymus, and lymph nodes, and made into a 
suspension in complete Freund's adjuvant (equal volumes of cell 
suspension and adjuvant). After five injections the mice de­
veloped ascites and could be tapped every 1 to 2 weeks. The cyto­
toxic titer of the ascites fluid was the same as the titer in the 
serum of these mice. Antisera were stored at -20 C. The serum 
thus prepared also contains weak activity against H-2K.34 and it 
is of current interest that this specificity may be an la-speci­
ficity and not a true H-2 specificity (17). 
Heteroantiserum. 
Goat anti-B6AFl lymphocyte serum (ALS) was prepared by a 
subcutaneous injection of B6AF1 lymphoid cells, in complete 
Freund's adjuvant into a goat, followed by weekly i.v. boosts of 
B6AF1 cells. The serum obtained 1 week after the fifth immuniza­
tion was heated at 560C for 45 min and stored at -20oC. 
Complement. 
Fresh frozen sera (-20 C) from rabbits were used as a source 
of complement. In the dilution used in the in vitro cytotoxic 
test (1:4) the complement was not toxic to mouse lymphoid cells, 
and, therefore, absorptions with mouse cells before use were un-
Abbreviations used in this paper: ALS, an ti-lymphocyte serum; 
MST, median survival time; SD, standard deviation; SAS, satura­
ted ammonium sulfate. 
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necessary. 
Fractionation procedures. 
The 7S antibodies were isolated from the hyperimmune sera, 
by Bio-gel A-0.5 m (Biorad Laboratories, Richmond, Calif.) gel 
filtration in a К 50/100 jacketed column (Pharmacia, Uppsala, 
Sweden), cooled with tap water (equilibrating buffer containing 
0.1 M Tris HCl, 0.2 M NaCl, 0.02% NaN3 at pH 8.0). A constant 
flow of 78 ml/hr was maintained by a pump. The fractions were col­
lected at 8-min intervals, with a LKB collector, and effluent 
transmission was recorded by continuous flow through an Uvicord 
II absorption photometer at 280 nm. The 7S fractions was concen­
trated by ultrafiltration (Amicon, XM 50 filter) to a protein 
content of about 3 mg/ml and equilibrated by passage through a 
Sephadex G-25 coarse column with 0.05 M citrate buffer at pH 6.0. 
Affinity chromatography. 
Specific antisera against mouse 7S IgGl, 7S IgG2, 7S IgG2a 
and 7S IgG2b (Meloy Laboratories, Springfield, Va.) were coupled 
to cyanogen bromide-activated Sepharose 4B (Pharmacia). 
Coupling procedure. 
Six milliliters of specific antiserum were mixed at room 
temperature with an equal volume of saturated ammonium sulfate 
(SAS) at pH 6.5. The resulting precipitate was washed three times 
with 50% SAS, dissolved in 6 ml 0.1 M NaHCCU and 0.5 M NaCl, and 
dialyzed against the same solution overnight. The ratio of CNBr-
Sepharose 4B and protein that would give optimal adsorption capa­
city was determined by coupling protein, precipitated from 6 ml 
antiserum (dissolved in 6 ml 0.1 M NaHCOj, 0.5 M NaCl) to 0.75, 
2.0, and 4.0 g CNBr-Sepharose 4B, respectively. Although 4 g 
CNBr-Sepharose 4B coupled far more protein, the adsorption capa­
city appeared almost nil. Best results were obtained with 0.75 g 
CNBr-Sepharose 4B. This amount was swollen on a glass filter and 
washed for 15 min with 10 M HCl. Thereafter, protein (about 100 
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mg) was coupled to the gel under gentle stirring. Coupling was 
completed in 2 hr. Uncoupled protein was mixed two more times with 
the same quantity of activated Sepharose 4B. After coupling, any 
remaining active groups in the gel were inactivated by incubating 
the gel with 1 M ethanol amine at pH 8.0 for 1 or 2 hr. To remove 
the non-covalently adsorbed protein after coupling, the gel was 
washed following a modification of van Munster's method (18), suc­
cessively with a) 0.1 M borate buffer at pH 8.0 + 1 M NaCl, b) 
0.1 M citrate buffer at pH 6.0, and c) 0.05 M citrate buffer at pH 
2.6 + 1 M NaCl. Thereafter, the gel was equilibrated with 0.05 M 
citrate buffer at pH 6.0. The Sepharose carrying the antibodies 
was packed in jacketed glass columns (2.6 χ 10 cm), cooled with 
tap water. 
Adsorption and elution. 
Samples of 3 ml 7S IgG solutions (protein content, 3 mg/ml) 
were applied to the column. The column was washed with 0.05 M ci­
trate buffer, pH 6.0, containing 0.02%NaN3,at a flow rate of 30 
ml/hr to remove unbound material. Adsorbed proteins were eluted 
with 0.05 M citrate buffer at pH 2.6 containing 1 M NaCl. The 
protein-containing eluate was collected immediately in 0.2 M 
phosphate buffer at pH 8.6 to avoid loss of biologic activity. 
After five runs, the columns were completely cleared of adsorbed 
proteins by washing with 0.05 M citrate buffer at pH 1.1, con­
taining 1 M NaCl. Before use, all fractions were equilibrated in 
salt by passage through a Sephadex G-25 coarse column, concentra­
ted by ultrafiltration and sterilized by means of membrane fil­
tering (Sartorius Membran Filter SM 11306, Göttingen, West Ger-
many) . 
Analytical procedures. 
All samples were analyzed by two-dimensional immunodiffusion 
with specific antisera produced in goats, directed against mouse 
7S IgGl, 7S IgG2, 7S IgG2a, 7S IgG2b, IgM, and IgA (Meloy) ac-
cording to Ouchterlony. For immunoelectrophoresis against goat 
anti-mouse serum (Meloy) the method of Scheidegger was used. 
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Isoelectric focusing was performed according to the method of 
Wrigley (19). 
Serology. 
The antisera and the different samples were tested in vitro 
with B10.D2 lymphoid cells, by using the trypan blue dye exclu­
sion method. Spleen cells were prepared free of red cells with 
g 
Tris-NH.Cl. One-tenth milliliter of cells (5 χ 10 /ml) were in­
cubated in tubes with equal volumes of antibody dilutions and 
rabbit complement (diluted 1:4) for 30 min at 37 С The titer was 
determined as the antiserum dilution giving 50% lysis. All titra­
tions were performed in duplicate. 
Skin grafts. 
B10.D2 tail skin was grafted onto B6AF1 recipients by the 
procedure described by Billingham and Medawar (20). In all experi­
ments donor and recipient were of the same sex. Only mice 6 to 12 
weeks of age were used. The casts were removed on the 7th day 
after transplantation. The fate of the graft was followed by dai­
ly inspection. Rejection was considered to be complete when no 
viable epidermis could be detected. The median survival times 
(MST) and the standard deviations (S.D.) were calculated by the 
method of Litchfield (21). 
Passive enhancement. 
Male B10.D2 tail skin was grafted onto male B6AF1 recipients. 
On days 0, 2, and 4 after skin grafting, the recipients received 
0.25 ml alloantiserum to H-2K.31, or different doses of the 7S 
IgG subclasses i.p. Control animals received equal volumes of 
normal B6AF1 serum. 
Hyperacute rejection. 
Female B10.D2 tail skin was grafted onto female B6AF1 re­
cipients. The survival of these grafts was prolonged by the in-
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Figure 1. Immunodiffusion of 7S IgGl and 7S IgG2 
against specific antisera. 
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jection of 0.25 ml ALS, on days 0, 2, and 4 after transplanta-
tion. All experiments were performed on well established grafts. 
On day 8 after grafting, the mice received a single i.v. inject-
ion of 0.25 ml alloantiserum or different doses of the 7S IgG 
subclasses, and 0.25 ml of rabbit complement. Hemorrhages and ne-
crotic changes in the grafts within 24 to 48 hr after injection 
were taken as criteria for hyperacute rejection (6). 
RESULTS 
Separation procedure and analysis of the samples. 
After gel filtration of whole alloantiserum, 3 ml of the 7S 
fraction, concentrated to 3 mg/ml and equilibrated to the start-
ing buffer, were applied to Sepharose columns containing anti-
bodies against 7S IgGl, 7S IgG2, respectively. Best results were 
obtained with a flow rate of 30 ml/hr. The maximal amount of pro-
tein eluted with 0.05 M citrate buffer at pH 2.6 + 1 M NaCl was 
about 1 mg. The proteins, after concentration to 15 mg/ml were 
tested by immunodiffusion and appeared to contain minimal amounts 
of contaminating protein of other subclasses. For example, the 
isolated 7S IgGl immunoglobulin was still slightly contaminated 
by 7S IgG2. For this reason, isolated 7S IgGl was further puri-
fied on the anti-7S IgG2 Sepharose column. 7S IgG2 was in the 
same way purified by passage over the anti-7S IgGl column. 
Thereafter, 7S IgGl as well as 7S IgG2, in a concentration 
of 15 mg/ml, appeared to be completely pure. Neither fraction 
contained IgA or IgM when tested by immunodiffusion (Fig. 1). On 
Immunoelectrophoresis against whole anti-mouse serum both frac-
tions appeared to be completely pure. A similar procedure was 
followed for the isolation of 7S IgG2a and 7S IgG2b from puri-
fied 7S IgG2 using ant:i-7S IgG2a and anti-7S IgG2b columns. The 
isolated immunoglobulins were also pure, as judged by immunodif-
fusion and immunoelectrophoresis. 
7S IgGl and 7S IgG2 were analyzed by isoelectric focusing. 
The patterns obtained with both subclasses of immunoglobulins 
were almost identical, as shown in Figure 2. 
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Figure 2. Isoelectric focusing patterns of the 7S fraction 
(obtained by gel filtration) and of the pure 7S IgGl and 
7S IgG2 subclasses. 
Biologic activity of the 7S IgG subclasses. 
In vitro cytotoxicity. 
The different subclasses were tested for their in vitro cy-
totoxicity with the trypan blue method. Before testing all samples 
were equilibrated with saline and concentrated by ultrafiltration 
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TABLE I 
Passive enhancement by antiserum to H-2K. 31 and by different doses 
of the IgG subclasses, in B6AF1 recipients of a B10.D2 skin graft 
Treatment No. of recipients M.S.T.+S.D. 
Normal mouse 
Anti-H-2K.3] 
7S IgGl 
7S IgG2 
7S IgG2a 
7S IgG2b 
serum 
19
 v
g 
38 ug 
187 цд 
375 yg 
750
 v
g 
9 yg 
19 yg 
93 yg 
187 yg 
375 yg 
937 yg 
1875 yg 
9 yg 
19 yg 
93 yg 
375 yg 
9 yg 
19 yg 
93 yg 
375 yg 
750 yg 
20 
10 
9 
11 
11 
10 
7 
11 
11 
11 
12 
10 
6 
8 
9 
10 
10 
10 
8 
10 
9 
9 
10 
days 
13.6+1.] 
19.0+1.] 
13.2+1.] 
13.5+1.] 
13.6+1.] 
17.0+1.] 
18.9+1.] 
14.7+1.] 
15.8+1.] 
17.6+1.] 
19.5+1.; 
19.6+1.] 
18.9+1.] 
19.5+1.: 
15.3+1.] 
15.0+1.] 
16.8+1.] 
19.0+1.; 
13.2+1.] 
13.4+1.1 
15.8+1.] 
17.0+1.] 
18.4+1.] 
L <0.002 
L NS 
L NS 
L NS 
L <0.002 
L <0.002 
L <0.05 
L <0.002 
L <0.002 
! <0.002 
L <0.002 
L <0.002 
! <0.002 
L <0.005 
L <0.05 
L <0.002 
г <o.oo2 
L NS 
L NS 
L <0.005 
L <0.002 
L <0.002 
Intraperitoneally on days 0, 2, and 4 after skin grafting. 
Level of significance (Student's t-test). 
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to a protein content of 2 mg/ml. Whole antiserum, 7S IgG2 and IgG 
2a had a cytotoxic titer of 1:512. The titer of 7S IgG2b was 
slightly less at different occasions, being 1:384. 7S IgGl showed 
no cytotoxic activity. The latter fraction was retested after a 
4-fold concentration. No cell lysis could be demonstrated and the 
complete absence of cytotoxic activity made it unlikely that the 
sample was contaminated with even minor amounts of 7S IgG2. 
B. Passive enhancement. 
The capacity of the different 7S IgG subclasses to induce en-
hancement was tested by injecting different doses of the samples, 
i.p., on days 0, 2, and 4 after transplantation. The results are 
given in table I and figure 3. Whole anti-H-2K.31 gave a signifi-
cant prolongation of skin graft survival (19.0 days). This is in 
accord with previous findings in this model (7). With all the sub-
classes a prolongation of skin graft survival could be obtained 
which did not differ significantly from the controls treated with 
whole antiserum. The dose-response curve for 7S IgG2 shows that 
even with low doses, a significant prolongation of graft survival 
time could be demonstrated. 
C. Hyperacute rejection. 
All 7S IgG subclasses were tested in vivo for their ability 
to induce hyperacute destruction of skin grafts, after their i.v. 
injection together with rabbit complement. As in the enhancement 
experiments, here also different doses were injected. The results 
are summarized in table II. No signs of destruction were seen a:Ç-
ter injection of 7S IgGl. Even with doses as high as 2000 pg, the 
survival of the grafts was the same as that of the control group 
(26.1 days). Hyperacute rejection could be induced with 7S IgG2, 
7S IgG2a and 7S IgG2b. After the administration of lower doses of 
7S IgG2 (38 ug) and 7S IgG2a (38 yg) some of the grafts remained 
unaffected while others showed patchy necrosis with local hemor-
rhages and eventual recovery after 2 days. The MST of the residual 
tissue was, however, not significantly different from that of the 
controls. As the table shows, some grafts were completely destroyed 
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Figure 3. Passive enhancement of B10.D2 skin grafts in B6AF1 recipients. Dose-response relationships 
of the different subclasses. 
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TABLE II 
Hyperacute rejection by the 7S IgG subclasses (isolated from anti­
serum to H-2K.31) in B6AF1 recipients'1 of a B10.D2 skin graft 
Treatment 
Controls0 
7S IgGl 
7S IgG2 
7S IgG2a 
7S IgG2b 
93 
375 
2000 
19 
38 
93 
187 
38 
93 
38 
93 
Ч 
vg 
v<3 
ug 
ug 
V<3 
ug 
vg 
vq 
V<3 
Ч 
No. of 
Recipients 
9 
5 
8 
4 
5 
5 
9 
4 d 
5 
5 
5 
4 d 
1 
5 
5 
5 
Hyperacute 
Rejection 
-
-
-
-
-
+
e 
+ 
+ 
+ 
+ 
-
+ 
MST+S.D. 
days 
26.1+1.2 
25.0+1.2 
25.0+1.1 
26.8+1.3 
26.7+1.2 
24.3+1.1 
24.6+1.1 
29.5+1.4 
Recipients treated with 0.25 ml ALS intraperitoneally on days 
0, 2, and 4 after skin grafting. 
Different doses of the samples together with 0.25 ml rabbit 
complement intravenously on day 8. 
Controls treated with 0.25 ml ALS i.p. on days 0, 2, and 4 and 
0.25 ml rabbit complement intravenously on day 8. 
Patchy necrosis with recovery in 2 days. 
+ indicates complete graft destruction within 48 hr after the 
injection of the antibody fractions together with complement. 
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at this dose level. 
DISCUSSION 
The results of our experiments show that it is possible to 
isolate pure 7S IgG subclasses by means of affinity chromatog-
raphy. However, to achieve this, several chromatographic steps 
were required. Thus, the 7S IgGl fraction was contaminated by 7S 
IgG2 after elution from the anti-7S IgGl Sepharose column. This 
might be due to nonspecific adsorption of 7S IgG2 to the column 
and, possibly, also to the fact that the commercially obtained 
antisera probably contain minor amounts of immune complexes of 
the other subclasses. These complexes are also bound to the column 
and their dissociation at low pH during the elution procedure re-
sults in the exposure of contaminating adsorption sites. The con-
taminating immunoglobulins could be removed by repeated adsorpt-
ions on the appropriate columns. It was important to assess the 
purity of the subclasses isolated, because small contaminations 
of the fractions might very well be able to influence the in vivo 
activity. 
The immunochemically pure 7S IgGl and 7S IgG2 subclasses 
showed an almost identical pattern on analysis with isoelectric 
focusing. This points to the marked physicochemical heterogeneity 
of both subclasses and it supports our previous finding that it 
is not possible to separate these subclasses by physicochemical 
procedures (14). 
All subclasses were able to induce enhancement of B10.D2 
skin grafts. The strongest activity was found in the 7S IgG2 im-
munoglobulin fraction. Within this subclass 7S IgG2a was somewhat 
more effective than 7S IgG2b, but both fractions induced signifi-
cant graft prolongation. These results are in accord with the 
findings of Fuller and Winn (9) who found that these subclasses 
could enhance the growth of a tumor allograft. However, in their 
experiments 7S IgGl seemed to be inactive since removal of the 
IgG2 subclass from the 7S globulin fraction resulted in loss of 
all enhancing activity. This latter result is in contrast with 
our findings. In the experiments described here 7S IgGl could 
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induce significant graft prolongation. The dose required to 
achieve this was, however, considerably higher than that of 7S 
IgG2. This dose-dependency might explain the failure of Fuller 
and Winn to demonstrate the enhancing activity of 7S IgGl. 
The dose-effect studies show that higher amounts of 7S IgGl 
than of 7S IgG2 were required to obtain a similar prolongation of 
graft survival. Care should be taken, however, to conclude that 
the 7S IgGl subclass has less enhancing activity. The results 
might very well be explained by the fact that only a minor part 
of the 7S IgGl fraction consists of specific anti-B10.D2 anti-
bodies. 
The capacity to induce hyperacute rejection of the skin 
grafts was only present in the 7S IgG2 subclass. As in the en-
hancement experiments 7S IgG2a was slightly more effective than 
7S IgG2b. Furthermore, the destructive capacity correlated well 
with the in vitro tests where also the cytotoxic titer of 7S 
IgG2a was higher than that of 7S IgG2b. The IS IgGl fraction was 
neither cytotoxic in vitro, nor could it induce hyperacute graft 
destruction even when doses as high as 2000 ug were used. Thus, 
hyperacute rejection could so far be induced only with the com-
plement-fixing 7S IgG2. The fact that fresh rabbit serum,which is 
an effective complement source was also necessary to obtain this 
effect strongly indicates that the hyperacute rejection in our 
model is a complement-dependent phenomenon. 
The results obtained do show clearly that the different and 
apparently opposite biologic effect of alloantisera cannot be 
explained by a difference in activity of the IgG subclasses. En-
hancing as well as destructive activity was demonstrated within 
a single subclass, i.e., 7S IgG2. These results do not exclude, 
however, the possibility that antibodies with a distinct specifi-
city are responsible for the opposite effects within this sub-
class. Recent studies (17, 22) suggest that enhancement is not 
due to antibodies directed against the classical serologically 
defined antigens, but to antibodies directed against la-antigens. 
The separation of these antibodies from a pure 7S IgG2 fraction 
and the resulting in vivo activity are reported in the accompany-
ing paper. 
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Chapter VI 
HYPERACUTE REJECTION AND ENHANCEMENT OF MOUSE 
SKIN GRAFTS BY ANTIBODIES WITH A DISTINCT SPECIFICITY 
Jan L.J. Jansen, Robert A.P. Koene, Gerard J. van Kamp, 
Jacq. F.H.M. Hagemann, and Paul G.A.B. Wijdeveld 
From the Department of Medicine, Division of Nephrology, 
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Pure 7S-IgG2 was prepared from B6AF1 anti-B10.D2 ascites 
fluid by affinity chromatography. This preparation was extensive-
ly absorbed with B10.D2 red blood cells to remove the antibodies 
directed against the serologically defined antigens of the ma^or 
histocompatibility complex. After absorption the serum had re-
tained m vitro cytotoxic activity against 45% of B10.D2 spleen 
cells. The absorbed and unabsorbed 7S-IgG2 antibodies were tested 
for their capacity to induce enhancement and, in the presence of 
rabbit complement, hyperacute rejection of B10.D2 skin grafts m 
B6AF1 recipient mice. The enhancing capacity of 7S-IgG2 was com-
pletely unimpaired after absorption. However, the absorbed prepa-
ration was unable to induce hyperacute rejection of the grafts 
even if very high doses were administered. The results show that 
hyperacute rejection of skin grafts in this model is mediated by 
antibodies directed against the serologically defined antigens 
(i.e., H-2K antigens) of the H-2 complex. They further support 
the hypothesis that immunologic enhancement is mediated by anti-
bodies directed against Ir-region-associated antigens. 
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Recent studies of immunologic enhancement suggest that anti­
bodies directed against antigens determined by genes which are 
located in the Ir-region of the major histocompatibility complex 
may be responsible for the enhancing capacities of mouse allo-
antisera. Staines et al. (1) showed that the enhancing capacity 
of an alloantiserum was fully retained after removal of the anti­
bodies against serologically defined antigens by absorption with 
erythrocytes. In an earlier study Davies and Alkins (2) had ob­
tained comparable results with heart allografts in the rat. After 
absorption, the antisera showed residual in vitro cytotoxicity 
against a selected population of lymphoid cells, presumably 
В cells. The assumption that the antibodies that remain after ab­
sorption are directed against Ir-region-associated antigens (la-
antigens) is supported by experiments in which identical cyto­
toxicity patterns could be demonstrated with antisera obtained by 
immunizations across Ir-region differences (3, 4). The la-antigens 
against which they were directed were not demonstrable on erythro­
cytes, muscle, brain tissue, and epidermal cells (4). 
Despite a considerable loss in cytotoxic activity the enhan­
cing capacity of the absorbed antisera was completely unimpaired 
in Staines' experiments. These findings raise the question whether, 
by removing the classical H-2 antibodies by absorption with red 
blood cells, the in vivo destructive capacities also are abolished. 
That antibodies can play an important role in the destruc­
tion of grafts is clearly illustrated in a variety of experimental 
models. Baldamus et al. (5) have shown that rat skin grafted onto 
mice can be acutely destroyed by the administration of a mouse 
anti-rat serum. In our experiments with skin allografts in the 
mouse we were able to demonstrate that an alloantiserum could not 
only induce a significant prolongation of graft survival due to 
enhancement but that it was also able to cause hyperacute rejec­
tion of the skin grafts if given together, with an effective com­
plement (6). These latter studies clearly showed that opposite ac­
tivities were present in the same alloantiserum. 
Abbreviations used in this paper: ALS, ant i-lymphocyte serum; 
MST, median survival time; SD, standard deviation; la-antigen, 
Ir-region-associated antigen. 
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In a previous study we have already demonstrated that these 
opposite effects cannot be ascribed only to the activities of 
different immunoglobulin (sub)classes (7). The present experi­
ments were undertaken to answer the question if the presence m 
this antiserum of antibodies with a distinct specificity may 
further explain these opposite biologic phenomena. Therefore, the 
pure 7S IgG2 fraction of a B6AF1 anti-B10.D2 serum, which 
possessed enhancing as well as destructive activity, was absorbed 
with B10.D2 erythrocytes. This absorbed fraction was tested for 
its ability to induce enhancement and hyperacute rejection of 
B10.D2 skin grafts. 
MATERIALS AND MFTHODS 
Animals. 
Inbred lines of B10.D2 n/Sn (H-2 ) were originally obtained 
from the Jackson Laboratory (Bar Harbor, Maine). B6AF1 hybrids 
were raised in our animal laboratory by matings of C57BL6/Ry(H-2T 
and A/HeJ(H-2a), both obtained from the Radiobiological Institute 
(Rijswijk, The Netherlands) and kept in our center by brother-
sister matings. 
Antisera. 
B6AF1 anti-B10.D2 alloantiserum and goat anti-B6AFl lympho­
cyte serum (ALS) were prepared as described in the previous paper 
(7). Fresh frozen sera (-20 C) fron rabbits were used as source 
of complement. 
Absorption procedure. 
B10.D2 red blood cells were purified from blood by the fol­
lowing procedure: 20 ml of freshly drawn blood, collected in CPD 
medium, were centnfuged at 700 χ G for 20 min, and the super­
natant and buffy coat were discarded. The pellet was washed three 
times in 0.16 M phosphate-buffered salt at pH 7.2, by centnfuga-
tion and discarding of the supernatant and white cell-rich upper 
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layers of the pellet. Thereafter the red cells were further puri­
fied by passage through a closely packed cotton wool column (9 χ 
2 cm) as described by Diepenhorst et al. (8). In this way more 
than 99% of leukocytes and platelets were removed. Fifteen milli­
liters of 7S IgG2 (protein content 3 mg/ml) obtained by affinity 
chromatography as described in the previous paper (7) were ab­
sorbed with these purified red blood cells during 3 hr at room 
temperature in sealed tubes, rotating end over end at 15 rpm. 
Five cycles, each with erythrocytes derived from 20 ml of blood, 
were needed before absorption was complete. Thereafter, the anti-
sera were sterilized by means of membrane filtering (Sartorius 
Membranfilter SM 11306, Göttingen, West Germany). 
Serology. 
After each absorption the in wLtvo cytotoxic activity was 
measured with B10.D2 lymphoid cells by using the trypan blue dye 
exclusion method (9). Briefly, spleen cells were prepared free of 
red cells with Tris-NH.Cl. One-tenth milliliter of cells (5 χ 10 / 
ml) was incubated in tubes with equal volumes of antibody dilu­
tions and rabbit complement for 30 min at 37 C. Protein concen­
tration of all samples was 3 mg/ml. All titrations were performed 
in duplicate. 
Skin grafts. 
B10.D2 tail skin was grafted onto B6AF1 recipients by the 
procedure described by Billingham and Medawar (10). The fate of 
the grafts was followed by daily inspection. The median survival. 
times (MST) and the standard deviations (S.D.) were calculated by 
the method of Litchfield (11). 
Passive enhancement. 
Male B6AF1 recipients of a male B10.D2 skin graft were 
treated on days 0, 2, and 4 after grafting, with different doses 
of 7S IgG2, or with different doses of the absorbed 7S IgG2 in­
jected i.p. Control animals received 0.25 ml normal B6AF1 serum. 
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Figure 1. In vitro cytotoxicity of 7S IgG2 before and after absorptions with B10.D2 red blood cells. 
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Hyperacute rejection. 
Female B10.D2 tail skin was grafted onto female B6AF1 reci-
pients. The survival of these grafts was prolonged by the in-
jection of 0.25 ml ALS on days 0, 2, and 4 after grafting. All 
experiments were performed on well established grafts. On day 8 
after grafting, recipient mice were injected i.v. with different 
doses of 7S IgG2 or absorbed 7S IgG2 (in 0.25 ml) together with 
0.25 ml of rabbit complement. Hemorrhages and necrotic changes in 
the grafts, within 24 to 48 hr after the injection, were taken as 
criteria for hyperacute rejection (6). 
RESULTS 
In vitro cytotoxicity. 
Figure 1 shows the in vitro cytotoxic activity of the anti-
serum before and after the absorptions. There was no further de-
crease in cytotoxicity after the fifth absorption cycle. The 
titration curves obtained are similar to those found by others 
(Staines et al. (1), Davies (2), and Hauptfeld et al. (4)). The 
maximal percentage of residual cell lysis obtained was 45% and 
this figure was constant in the first five dilutions. 7S IgG2 
that were absorbed six times, were used in the in vivo experi-
ments . 
Biological activity in vivo 
A. Passive enhancement. 
The enhancing capacities of the 7S IgG2 and the absorbed 
7S IgG2 were tested by the injection of different doses, i.p., on 
days 0, 2, and 4 after grafting. The results are summarized in 
Table I. Control animals received 0.25 ml normal B6AF1 serum. As 
demonstrated, whole 7S IgG2 as well as the absorbed 7S IgG2 were 
able to induce a significant prolongation of graft survival. These 
findings are similar to those of Staines et al. (1). Furthermore, 
the dose-response curves show that the absorbed antiserum was as 
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TABLE I 
Passive enhancement by different doses of 7S IgG2 and ab­
sorbed 7S IgGZ antibodies in B6AF1 recipients of a B10.DZ 
Skin graft 
Treat­
ment 
vg 
9 
19 
94 
187 
No. of 
recip­
ients 
20 
11 
11 
11 
12 
7S IgG2 
M.S.T.+S.D. 
days 
13.6+1.1 
14.7+1.1 
15.8+1.1 
17.6+1.1 
19.5+1.2 
No. of 
recip­
ients 
20 
9 
9 
8 
9 
Absorbed 7S 
M.S.Τ.+S.] 
days 
13.6+1.1 
14.4+1.1 
14.8+1.1 
17.7+1.1 
18.7+1.1 
IgG2 
3. Р Ь 
NS C 
NS 
NS 
NS 
Intraperitoneally, on days 0, 2, and 4 after skin grafting. 
Level of significance (Student's t-test) of differences 
between both groups. 
NS, not significant. 
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TABLE II 
Destructive capacity of 7S IgG2 and absorbed 7S IgG2 anti-
bodies in B6AF1 recipients of a B10.D2 skin graft 
Treatment 
No. of 
Recipients 
8 
9 
4 
5 
5 
5 
4 
4 
5 
Hyper-
acute 
Rejection 
-
-
-
+
d 
+ 
+ 
-
-
_ 
M.S.T.+S.D 
days 
26.1+1.2 
26.7+1.2 
24.3+1.1 
28.1+1.1 
26.0+1.2 
27.0+1.3 
Controls 
7S IgG2 
Absorbed 
7S IgG2 
vg 
19 
38 
94 
187 
94 
375 
1125 
Recipients treated with 0.25 ml ALS, intraperitoneally, on 
days 0, 2, and 4 after skin grafting. 
On day 8, 0.25 ml of serum fraction together with 0.25 ml 
rabbit complement was injected intravenously. 
Controls treated with 0.25 ml ALS i.p. on days 0, 2, and 4 
and with 0.25 ml rabbit complement intravenously on day 8 
after grafting. 
+ indicates complete graft destruction within 48 hr after the 
injection of antibody fractions together with complement. 
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effective as the unabsorbed 7S IgG2 in inducing prolongation of 
graft survival. 
В. Hyperacute rejection. 
The capacity of the 7S IgG2 and the absorbed 7S IgG2 to in­
duce hyperacute destruction of the skin grafts was tested by i.v. 
injections of different doses of each preparation together with 
rabbit complement on day 8 after grafting. The results are sum­
marized in Table II. As demonstrated and as known from previous 
experiments (7) the unabsorbed 7S IgG2 antibodies caused complete 
damage of the grafts within 24 to 48 hr. After absorption, no in 
vivo destructive activity could be seen. Even with doses over 10 
times higher (1125 ug) than the lowest dose (94 yg) of the unab­
sorbed fraction that induced complete destruction in all recipi­
ents, no destructive effects could be detected and graft survival 
was not significantly different from that in the controls. 
DISCUSSION 
The results of these experiments clearly show that the in 
vivo destructive activity of the 7S TçG2 can be completely re-
moved by absorption with erythrocytes. Even very high doses of 
absorbed antiserum are unable to induce hyperacute rejection. In 
spite of this, the absorbed 7S IgG2 antibodies retain cytotoxici-
ty in vitro which is directed only against a proportion of lympho-
cytes. Furthermore, the enhancing capacity is completely unaltered. 
In the strain combination used in our experimental model 
there is only a difference in the K, Ir-IA and Ir-IB sub-regions 
of the major histocompatibility complex. Antisera obtained by 
cross-immunization contain, therefore, only antibodies against the 
antigenic products of these regions. Absorption of these sera with 
red blood cells (lacking the la antigens in rodents) implies that 
only antibodies against H-2K antigens are removed. This is 
supported by the results of the in vitro cytotoxic tests, which 
show patterns that are remarkably similar to those obtained by 
Klein et al. (3) and Hauptfeld et al. (4) with sera directed only 
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against Ir-antigens. Thus, the most important conclusion is that 
hyperacute rejection of skin grafts in our model must be mediated 
by antibodies directed against the К region antigens of the H-2 
complex. The complete absence of destruction, even with very high 
doses of the absorbed antiserum makes it very unlikely that anti­
bodies directed against la antigens are involved in this process. 
It does not exclude the possibility that la antigens are present 
on the vascular endothelium or on the epithelial cells of the 
graft, but, if so, they may be present in such a low concentra­
tion that binding of antibodies does not lead to an effective 
complement activation resulting in cell destruction. 
It is clear from our experiments that the removal of anti­
bodies directed against К region antigens by absorption did not 
lead to a decrease in enhancing capacity. This is most clearly 
illustrated by the results of the dose-effect study in which the 
same prolongation of graft survival was obtained if comparable 
doses of 7S IgG2 and absorbed 7S IgG2 were administered. There­
fore, the enhancing activity of the antiserum might be attributed 
to antibodies directed against la antigens. As is known from other 
studies, enhancement induced in this model is a specific phenome­
non (12). Our results correlate well with the findings of Staines 
et al. (1) and of Davies and Alkins (2). 
The strain combination used in the current study is slightly 
different from that used by Staines et al. They used B10.D2 lym­
phocytes to immunize BIO.A recipients and on the basis of current 
knowledge of the different la specificities (13) , such immuni­
zation should give rise only to antibodies directed against spe­
cificity la.8. Differences in la-specificities have sofar not been' 
demonstrated in the strain combination used in our model. Anti­
bodies to la.8 cannot be present since the H-2 haplotype that 
carries la.8 is represented in the B6AF1 recipient. However, the 
results of the titration of the absorbed preparation suggest that 
anti la-antibodies are present in the B6AF1 anti B10.D2 antiserum. 
These might be directed against specificities that are not yet 
determined and that must be located in the Ir-IA or Ir-IB sub-
regions since the strain combination used differs in these regions. 
Although the closely comparable dose-effect curves of the 
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absorbed and unabsorbed 7S IgG2 do suggest that all enhancing ac-
tivity is mediated by antibodies against la antigens, the experi-
ments furnish no direct evidence that antibodies against K-region 
antigens completely lack enhancing activity. To study this, one 
must isolate pure preparations of these latter antibodies; this 
is currently being carried out in our laboratory. 
Our experiments are pertinent to the hypothesis of Bach (14), 
who believes that the lymphocyte-defined antigens, probably coded 
by Ir-region genes, play a predominant role in the recognition 
phase of the allograft reaction, whereas serologically defined 
antigens are only involved in the efferent arc. However, recent 
findings of Klein et al. (15) indicate that this might be an over^ 
simplification, because they reported that an H-2K antigenic 
difference can elicit cellular immune reactions in the absence of 
Ir-region differences. Nevertheless, our findings are consistent 
with Bach's hypothesis since we have shown that the serologically 
defined antigens are the targets for the antibody-mediated graft 
destruction and that antibodies against la-antigens are complete-
ly ineffective in this effector process. 
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Chapter VII 
RELEVANCE OF THE RESULTS FOR CLINICAL TRANSPLANTATION 
The data of the experiments reported in the preceding chap­
ters, show that two populations of antibodies, each with a dis­
tinct specificity, are present in the anti-B10.D2 alloantiserum 
used. There are, on the one hand, antibodies directed against the 
serologically defined (SD) antigens, coded for by genes from the 
К region, and on the other hand, antibodies directed against the 
I region associated (la) antigens. For the latter group of anti­
gens it is assumed that they form at least partly also the group 
of so-called lymphocyte-defined (LD) antigens. The results of our 
experiments together with recent data on the role of antibodies 
in transplantation provided by Davies and Alkins (1974) and by 
Staines et al. (1974) strongly suggest that antibodies, directed 
against the SD antigens, are responsible for the destructive 
effects on the grafts, whereas antibodies directed against la-
antigens are mediators of immunological enhancement, resulting in 
prolongation of graft survival. 
It is not self-evident that these findings are also applica­
ble to the human system, but some data from human research strong­
ly support the assumption that the H-2 system in the mouse is 
analogous to the HL-Α system in man, as far as its function in the 
allograft reaction is concerned. In man, too, two antibody popula­
tions have been demonstrated in alloimmune sera (van Leeuwen et al., 
1973; van Rood et al., 1975a). As in mice, these two populations 
of antibodies appeared to be directed against SD antigens, on the 
one side, and against LD antigens on the other side. The charac-
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teristics of these latter antibodies are remarkably similar to 
those in mice. They, too, are only demonstrable on part of the 
lymphocyte population as shown by van Rood et al. (1975a). There­
fore, it may be assumed that these antibodies are the equivalents 
of the mouse anti-la-antibodies. 
Other important data, furnishing evidence for the similarity 
of the H-2 system in the mouse and the HL-Α system in man, come 
from the in vitro experiments of Eysvoogel et al. (1973) . In family 
studies with members in which recombination between the Four, the 
LA and the MLC locus had occurred, he could demonstrate that MLC 
activation was predominantly obtained by LD antigenic differences, 
whereas cell-mediated lymphocytolysis (CML) was directed against 
the SD antigens present on the target cells. Similar results were 
reported by Bach (1973) . These in vitro results in man seem to 
correlate very well with our findings in mice. 
In in vivo studies in man, it could be demonstrated that in 
the homograft reaction, in the same way as in the mouse, several 
closely linked chromosomal regions were involved. The important 
influence of the MLC locus on skin graft survival in man could 
clearly be demonstrated by van Rood et al. (1973). Also the sur­
vival of kidney grafts showed a close positive correlation with 
the results of MLC studies (Hamburger et al., 1971). From these 
latter data it appeared that MLC identity resulted in prolongation 
of·graft survival. 
On the basis of these data from in vivo and in vitro models, 
it was hypothesized by van Rood et al. (1975b) that in man the 
induction of allograft sensitivity was mediated by LD determinants 
while graft destruction that follows allograft sensitization is 
caused by activated lymphocytes and/or antibodies directed against 
the SD and not the LD determinants. 
The striking similarities of the immune mechanisms in trans­
plantation processes in mouse and man lead to the postulate that 
results of experiments in mice concerning the transplantation 
immunology may be of great value for human transplantation research. 
The mouse offers great advantages owing to the fact that the 
availability of unlimited numbers of genetically identical animals 
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makes it possible to repeat the experiments, an opportunity that 
is not frequently encountered in clinical medicine. 
In present day clinical transplantation, especielly kidney 
transplantation, the problems are no longer of a surgical nature. 
The most important obstacles are formed by the rejection process 
and by the complications resulting from the non-specific immuno-
suppressive therapy. The new insights in the immune processes 
occurring in transplantation, especially those with regard to 
antigenic structures in relation to the efferent and afferent arc 
of the immune response, may prove to be of great benefit for the 
recipient of a graft. There is already a growing host of evidence 
that tissue typing for SD and LD determinants shows a good corre-
lation with graft survival. 
In the search for effective specific immunosupprsssive thera-
py that is applicable to clinical transplantation, enhancement 
seems to hold great promises. In the experiments reported here, 
it was demonstrated that in the mouse, it is feasible to prepare 
an enhancing antiserum from which the destructive or cytotoxic 
antibodies are removed completely. In this light, it is encouraging 
that recent data of van Rood et al. (1975a) demonstrate that also 
from human alloantisera antibodies directed against SD antigens 
can be removed by absorption with platelets. If it would be pos-
sible to prepare in this way enhancing antisera that are suitable 
for clinical use, the prognosis of graft recipients could be great-
ly improved. It seems justified to expect that these different 
but parallel lines of research by complementing each other will 
lead to a better care for the patient with an organ transplant in 
the near future. 
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SUMMARY 
The major problem encountered in clinical transplantation 
is the rejection of the grafted organ. Although tissue typing and 
the selection of appropriate recipients has resulted in improved 
graft survival it must be concluded that in most cases it is not 
possible to prevent rejections without the use of strong acting 
and potentially harmful immunosuppressive agents. The treatment 
implies, at this moment, the administration of non-specific immu-
nosuppressive drugs. Not only the defense mechanisms directed 
against the transplanted organs are impaired by this therapy, but 
at the same time the total immune competence of the graft reci-
pient himself is jeopardized. The complications resulting from 
this treatment, especially the frequent occurrence of serious 
infections, often brings the patient in a life threatening situa-
tion. For these reasons, investigators have since decennia searched 
for a form of therapy that would only suppress the immune reacti-
vity to the graft, while leaving the immune capacity of the re-
cipient otherwise unimpaired. Such a form of specific immuno-
suppression has already been known for a long time in animal models. 
In a variety of experimental circumstances it appeared possible 
to induce a significant prolongation of graft survival by the 
administration of antisera specifically directed against the graft 
antigens. This form of specific immune blockage was called en-
hancement. It is an interesting finding, however, that in several 
models enhancing antisera have also a destructive effect resulting 
in acute rejection of the grafted organ. 
So it seems likely that these antisera contain different 
populations of antibodies responsible for these apparently opposite 
effects on the grafts. 
In this study the results are reported of a research in which 
an antiserum was separated in different fractions of antibodies 
by various methods in order to obtain a separation of transplanta-
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tion biologie activities. The experiments were carried out in a 
skin graft model in the mouse. In this model the B10.D2 (H-2 ) 
strain was used as the donor of the skin grafts, and the B6AF1 
hybrid (H-2 χ H-2 ) strain as the recipient. In this strain com­
bination it was possible by administration of B6AFl-anti-B10.D2-
serum to induce enhancement of the skin grafts. Hyperacute des­
truction of the grafts could be induced by the same antiserum if 
an effective complement was injected simultaneously. 
In earlier reports in the literature it was supposed that 
different classes and subclasses of antibodies would be responsible 
for the different biologic actions. Especially with respect to en­
hancement many investigators tried to obtain active antibody 
fractions by the isolation of classes or subclasses of immunoglobu­
lins. In many instances it was reported that by fractionation of 
antiserum with physicochemical methods highly pure (sub)classes 
could be obtained which had a different effect on graft survival. 
The results of this sort of experiments are, however, confusing 
and often contradictory. In our experiments we separated the B6AF1-
anti-B10.D2-serum with gel filtration and ion-exchange chromato­
graphy. In this way 5 fractions could be isolated, which showed 
no contaminating overlap as was demonstrated by analytical iso 
electric focusing. In spite of this complete physicochemical sepa­
ration all the fractions were found to contain immunoglobulins of 
several subclasses. Moreover, the results of the in vitro and 
in vivo experiments also failed to demonstrate a separation of 
biologic activities, because with all fractions enhancement as well 
as hyperacute rejection could be induced. These findings are not 
surprising in view of what is known today about the physicochemi­
cal properties of the immunoglobulins. Especially in the mouse 
this group of proteins shows a marked heterogeneity in physico-
chemical behaviour. It must therefore be assumed that isolation of 
pure (sub)classes of antibodies by physicochemical means is not 
possible. This implies that antibody fractions obtained in this 
way must be contaminated with other (sub)classes. It seems, there­
fore, very likely that the contradictory results reported in the 
literature can be accounted for by the fact that in these experi­
ments contaminated (sub) class fractions were tested. 
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A more sophisticated method for the isolation of pure frac­
tions of proteins is the affinity chromatography with insolubili-
zed proteins. Using Sepharose 4B as a carrier matrix for specific 
antibodies directed against the mouse IgG subclasses, we succeeded 
in isolating the pure subclasses IgGl/ IgG2, IgG2a and IgG2b. When 
tested, even in high concentrations, the isolated fractions 
appeared absolutely pure on analysis with immunodiffusion and 
Immunoelectrophoresis. This made it possible for us to study the 
biologic activities of these pure immunoglobulins in vitro as well 
as in vivo. It could be demonstrated that only IgG2 (IgG2a as well 
as IgG2b) had in vitro cytotoxic activity. IgGl lacked the ability 
to cause lysis of B10.D2 lymphoid cells in vitro. These findings 
correlated well with the in vivo experiments in which hyperacute 
destruction of skin grafts was induced. Analogous to the results 
of the cytotoxic tests, it was found that the destructive activity 
was only present in the IgG2 fraction. We were unable to induce 
the slightest sign of skin graft rejection, even if very high 
doses of IgGl were administered. Enhancement could be elicited with 
all the subclasses tested. Although it appeared possible to demon­
strate differences in the actions of the IgGl and IgG2 subclasses, 
it was, nevertheless, clear that two opposite biological transplan­
tation activities could be present within a single subclass, name­
ly IgG2. We attempted, therefore, to obtain a further separation 
of these IgG2 immunoglobulins. 
Recent data suggest that a complexity of immune mechanisms is 
involved in the rejection process. It is assumed assumed that 
lymphocyte defined (LD) antigens determined by genes in the I re-, 
gion (la antigens) of the mouse major histocompatibility complex 
are involved in the sensitizing or afferent phase of the allograft 
reaction, while serologically defined (SD) antigens, coded for by 
genes from the К and D regions of this complex, are the targets 
for the killing phase, or effector arc of the rejection process. 
There is preliminary evidence that enhancement is mediated by a 
blockage of the la antigens by antibodies. In the strain combi­
nation used in our experiments, donor and recipient mice differed 
in the К region as well as in the Ir-IA and Ir-IB subregions, which 
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made it likely that antibodies against К as well as against la 
antigens were present in the antiserum. In our further experiments 
we attempted to separate the anti-K antibodies from the anti-la 
antibodies. In these attempts use was made of the fact that in the 
mouse la antigens are not expressed on the cell surface of red 
blood cells. By extensive absorptions of the IgG2 immunoglobulin 
fraction with B10.D2 red blood cells, it was possible to complete­
ly remove the antibodies directed against the serologically de­
fined К region antigens (in our model H-2K.31). It was demonstra­
ted that the removal of these antibodies resulted in a complete 
loss of the destructive capacity of the IgG2 fraction whereas the 
enhancing activity was unaffected. It must be concluded that cyto­
toxic IgG2 antibodies directed against the SD histocompatibility 
antigens are responsible for the cytotoxic and destructive actions 
of the antiserum, whereas enhancement is mediated by antibodies 
directed against the la antigens. 
The la antigen detected in the study described here repre­
sents a new specificity because la antigenic differences have so 
far not been described in this donor-recipient combination. 
The results are closely analogous to those obtained in man, 
where probably also two populations of antibodies with a different 
specificity and an opposite biological activity are involved. This 
implies that experiments in the mouse model can serve as a very 
useful tool to obtain a better insight into the mechanism of the 
rejection process which may ultimately lead to improved graft 
prognosis in human transplantation. 
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SAMENVATTING 
Het belangrijkste probleem waarmee men geconfronteerd wordt 
in de klinische transplantatie, is de afstoting van het getrans-
planteerde orgaan. Ofschoon weefseltypering en selectie van pas-
sende donor-ontvanger combinaties heeft geleid tot een verbetering 
van de transplantaatoverleving, moet toch geconcludeerd worden 
dat het in de meeste gevallen niet mogelijk is om afstoting te 
voorkomen, zonder het gebruik van sterk werkende en potentieel 
schadelijke medicamenten. Momenteel bestaat deze therapie uit de 
toediening van niet specifiek werkende immunosuppressieve genees-
middelen. Hierdoor wordt niet alleen de afweer tegen het getrans-
planteerde orgaan onderdrukt, maar tevens het totale immunologische 
reactievermogen van de ontvanger. De complicaties die voortvloeien 
uit een dergelijke behandeling, vooral de frekwent optredende 
ernstige infecties, brengen de patient vaak in levensbedreigende 
situaties. Om deze redenen is sedert decennia gezocht naar een 
vorm van behandeling die de immuunreactiviteit ten opzichte van 
het getransplanteerde orgaan zou kunnen verminderen zonder daarbij 
de totale immunologische afweer van de ontvanger in gevaar te 
brengen. 
Zulk een vorm van specifieke immuunsuppressie is in dier-
experimentele omstandigheden reeds lang bekend. In vele proefdier-
modellen is het mogelijk een significante verlenging van trans-
plantaatoverleving te induceren door de toediening van antisera 
die specifiek gericht zijn tegen antigene structuren voorkomend 
op het transplantaat. Deze vorm van specifieke immunologische blok-
kade wordt enhancement genoemd. Een interessante bevinding is 
echter dat in bepaalde diermodellen enhancing antisera tevens een 
destructief effect hebben, hetgeen dan kan resulteren in een acute 
afstoting van het getransplanteerde orgaan. Het lijkt dus waar-
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schijnlijk dat deze antisera verschillende soorten antilichamen 
bevatten die verantwoordelijk zijn voor deze schijnbaar tegenge­
stelde effecten op het transplantaat. 
In deze studie worden de resultaten beschreven van een onder­
zoek waarin op verschillende manieren een antiserum in antilichaam-
fracties werd gescheiden, met het doel een scheiding van trans­
plantatie-biologische aktiviteiten te bewerkstelligen. 
De experimenten werden uitgevoerd in een huidtransplantatie-
model bij de muis. In dit model werd de B10.D2 (H-2 ) stam ge­
bruikt als donor van het huidtransplantaat en de B6AF1 hybride 
(H-2 χ H-2 ) stam als ontvanger. In deze stam combinatie was het 
mogelijk enhancement van de huidtransplantaten te induceren door 
toediening van B6AFl-anti-B10.D2-serum. Met ditzelfde antiserum 
kon ook hyperacute transplantaatafstoting worden opgewekt indien 
tegelijk met het antiserum een effectief complement werd geïnji-
ceerd. 
Eerdere gegevens uit de literatuur veronderstellen dat ver-
schillende klassen en subklassen van antilichamen verantwoordelijk 
zouden zijn voor do verschillende biologische aktiviteiten. Vooral 
wat betreft enhancement is door vele onderzoekers getracht actieve 
antilichaamfracties te verkrijgen door isolering van klassen of 
subklassen van immuunglobulinen. Vaak wordt vermeld dat door anti-
serum fractionering met fysisch-chemische methoden, zuivere (sub)-
klassen verkregen werden die een verschillend effect op de trans-
pl'antaatoverleving vertoonden. De resultaten uit dit soort experi-
menten zijn echter verwarrend en vaak tegenstrijdig. In onze 
experimenten werd het B6AFl-anti-B10.D2-serum gescheiden met gel 
filtratie en met ionenwisselaar chromatografie. Op deze manier 
konden 5 fracties volledig worden gescheiden, zoals werd aangetoond 
met analytisch isoelectrisch focuseren. Ondanks deze complete 
fysisch-chemische scheiding bleken al deze fracties, immuunglobu-
linen uit verschillende subklassen te bevatten. Bovendien bleek 
uit de resultaten van de in vitro en in vivo experimenten dat gëén 
scheiding van biologische aktiviteit werd verkregen. Met alle 
fracties kon zowel enhancement als hyperacute afstoting worden op-
gewekt. 
Deze bevindingen wekken geen verwondering als men ze beschouwt 
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in het licht van hetgeen momenteel bekend is over de fysisch-che-
mische eigenschappen van de immuunglobulinen. Met name bij de muis 
vertoont deze groep van eiwitten een sterke heterogeniteit in 
fysisch-chemisch gedrag. Men moet daarom aannemen dat een isolering 
van zuivere (sub)klassen van antilichamen met fysisch-chemische 
methodieken niet mogelijk is. Dit houdt tevens in dat antilichaam-
fracties die op deze manier verkregen zijn, steeds verschillende 
subklassen zullen bevatten. Het lijkt dan ook erg waarschijnlijk 
dat de tegenstrijdige resultaten uit de literatuur verklaard moeten 
worden uit het feit dat in deze experimenten gecontamineerde (sub)-
klasse fracties werden getest. 
Een modernere methode voor de isolering van zuivere fracties 
eiwitten is de affiniteitschromatografie. Met behulp van Sepharose 
4B als drager voor specifieke antilichamen gericht tegen de IgG 
subklassen van de muis, werden de zuivere subklassen IgGl, IgG2, 
IgG2a en IgG2b geïsoleerd. Deze fracties bleken volkomen zuiver 
bij analyse met immunodiffusie en immunoelectroforese, zelfs in-
dien ze getest werden in hoge concentraties. Dit bood de mogelijk-
heid om de biologische eigenschappen van deze zuivere immuunglo-
bulinen zowel in vitro als in vivo te bestuderen. Aangetoond werd 
dat IgG2 (IgG2a en IgG2b) in vitro cytotoxische aktiviteit ver-
toonde. IgGl miste het vermogen om lysis van B10.D2 lymphocyten 
in vitro te veroorzaken. Deze bevindingen correleerden goed met de 
resultaten van de in vivo experimenten, waarbij hyperacute afsto-
ting van huidtransplantaten werd geïnduceerd. Analoog aan de re-
sultaten van de cytotoxiciteitstest bleek dat destructie van de 
transplantaten verkregen kon worden met de IgG2 fractie. Met IgGl 
kon, zelfs indien zeer hoge doses werden gebruikt, geen enkel 
teken van transplantantbeschadiging worden opgewekt. Enhancement 
kon met alle subklassen verkregen worden. Ofschoon het dus moge-
lijk bleek een verschil in aktiviteit tussen IgGl en IgG2 aan te 
tonen was het desondanks duidelijk, dat twee tegenovergestelde 
biologische transplantatie-sktiviteiten aanwezig konden zijn binnen 
één enkele subklasse, in casu IgG2. Getracht werd daarom een ver-
dere scheiding van de IgG2 immuunglobulines te verkrijgen. 
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Recente gegevens suggereren dat een complexiteit van immuun-
mechanismen betrokken is bij het afstotingsproces. Aangenomen 
wordt dat LD antigenen, die gedetermineerd worden door genen uit 
de I regio van het belangrijkste histocompatibiliteitscomplex van 
de muis (Ia antigenen), betrokken zijn bij de sensibiliserings-
of afferente fase van de transplantatiereaktie, terwijl SD anti­
genen, gecodeerd door genen uit de К en D regio's van dit complex, 
het doelwit zijn van de "killing" of efferente fase van de afsto­
ting. Het lijkt mogelijk dat enhancement wordt veroorzaakt door 
blokkerende antilichamen gericht tegen de Ia antigenen. 
In de in ons onderzoek gebruikte stamcombinatie verschillen 
de donor en de ontvanger in de К regio en in de Ir-1A en Ir-1B 
subregio's, waardoor het waarschijnlijk is dat antilichamen aan­
wezig zijn in het antiserum die gericht zijn tegen zowel К als I 
regio antigenen. In de experimenten werden deze anti-K antilicha­
men gescheiden van de anti-Ia antilichamen. Hierbij werd gebruik 
gemaakt van het feit dat bij de muis Ia antigenen ontbreken op het 
celoppervlak van rode bloedcellen. Door uitgebreide absorptie van 
de IgG2 immuunglobuline fractie met B10.D2 erytrocyten was het mo­
gelijk de antilichamen die gericht waren tegen de (SD) К regio 
antigenen (in ons model anti-H-2K.31) volledig te verwijderen. 
Verwijdering van deze antilichamen resulteerde in een complete 
verdwijning van de destructieve aktiviteit van de IgG2 fracties, 
terwijl de enhancing aktiviteit onveranderd aanwezig bleef. Hieruit 
moet geconcludeerd worden dat cytotoxische IgG2 antilichamen, ge­
richt tegen de serologisch gedefinieerde histocompatibiliteits-
antigenen, verantwoordelijk zijn voor de destructieve aktiviteit 
van het antiserum, terwijl enhancement veroorzaakt wordt door 
antilichamen gericht tegen Ia antigenen. 
Het Ia antigeen, ontdekt in deze studie, is een nieuwe spe­
cificiteit, daar Ia antigene verschillen tot dusverre niet be­
schreven zijn in deze donor-ontvanger combinatie. 
De vermelde resultaten correleren nauw met die bij de mens, 
waar zeer waarschijnlijk ook twee populaties antilichamen met een 
verschillende specificiteit en een verschillende biologische akti­
viteit betrokken zijn bij het afstotingsproces. Dit houdt in dat 
experimenten bij de muis kunnen dienen als een bruikbaar middel 
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om een beter inzicht te verkrijgen in het mechanisme van het af-
stotingsproces, hetgeen uiteindelijk kan leiden tot een verbeterde 
prognose van transplantaten bij de mens. 
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STELLINGEN 
1 
Immuunglobulinen hebben zo dikwijls fysisch-chemische eigenschdp-
pen gemeen, dat fysisch-chemische scheidingsmethoden niet toe­
reikend zijn om zuivere klassen en subklassen met specifіьке 
biologische aktiviteiten te scheiden. Dit gegeven verklaart veel 
tegenstrijdige bevindingen op het gebied van de transplantât}e-
biologie. 
- dit proefschrift 
2 
Het is onjuist te menen dat het effect van een imrruunglobuline op 
transplantaatoverleving uitsluitend afhankelijk zou zijn van de 
(sub)klasse. Binnen éën (sub)klasse kunnen zowel immuunglobulinen 
voorkomen die een verlenging (enhancement) als imiruunglobulinen 
die een verkorting (rejectie) teweegbrengen. Het effect wordt 
tevens bepaald door de specificiteit van het transplantatie anti-
geen waartegen het betreffende immuunglobuline gericht is. 
- dit proefschrift 
3 
Bij de destructieve aktiviteit van alloantisera op huidtransplan-
taten bij de muis speelt het Ia systeem geen rol. 
- dit proefschrift 
4 
Donornefrectomie met het oog op niertransplantatie dient alleen 
door daartoe geschoolde chirurgen, m samenwerking met preservatie 
deskundigen verricht te worden. 
5 
Bij lijders aan een nefrotisch syndroom vermindert indomethacine 
dikwijls niet alleen de Proteinurie, maar ook het effect van 
natriuretica. Dit tweeledig effect dient men bij de toepassing 
van het medicament te bedenken. 
- R.G.W.L. Tiggeler e.a. (1973) Neth. J. Med. 16_, 61 
6 
Pogingen het aantal postmortale nierdonoren te verhogen dienen 
zich niet alleen te richten op de publieke opinie maar evenzeer 
op de artsen. Hen zal het belang van niertransplantatie en de wegen 
waarlangs deze kan worden verwezenlijkt duidelijk voor ogen moeten 
staan. 
7 
Voor goed dierexperimenteel onderzoek is inbreng van dierenartsen 
en biotechnici een noodzakelijk voorwaarde. 
8 
De opvatting dat urineweginfecties bij patiënten met een gestoorde 
nierfunktie niet effectief behandeld zouden kunnen worden met 
doxycycline is alleen gebaseerd op aanvechtbare theoretische over-
wegingen en niet op de resultaten van klinische waarnemingen. 
9 
Een nierbiopsie dient alleen dan plaats te vinden wanneer het mo-
gelijk is naast lichtmicroscopisch tevens immunohistochemisch en 
electronenoptisch onderzoek te verrichten. 
10 
Het is onbekend of het aan tolbutamide en phenformin toegetchre-
ven verhoogde sterfte risico aan hart-vaatziekten ook geldt voor 
andere orale antidiabetica. De conclusie van Touber dat fu. t "on-
juist en onverantwoord zou zijn, de orale antidiabetica nog langer 
aj-s geneesmddel aan te duiden, aan te prijzen, of voor te schrij-
ven" is daarom vooralsnog onjuist en onverantwoord. 
- J.L. Touber (1975) Ned. T. Geneesk. 119, 1506 
11 
Een klinisch werkzaam wetenschappelijk medewerker fungeert gezien 
zijn takenpakket (1) patiëntenzorg, 2) onderwijs, 3) wetenschappe-
lijk onderzoek, 4) administratie en 5) eigen vorming) vaak als 
een schaap met vijf poten. Onvoldoende vraagt men zich af of dit 
schaap zich nog wel evenwichtig kan voortbewegen. 
J.L.J. Jansen Nijmegen, 11 december 1975 



